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ABSTRACT
Background: Prenatal vitamin use is recommended as a necessary
supplement prior to conception and throughout pregnancy. Multivitamin use in
early pregnancy can significantly reduce risks for birth defects: cardiovascular
defects,1, 2 limb defect,3-5 urinary tract abnormalities,4, 6 orofacial clefts,7, 8 and
neural tube defects (NTDs). 2, 9-16 Sixty-nine to seventy-eight percent of women
take vitamins after pregnancy recognition, while only 23-35% of women in the
U.S. start to use vitamins before pregnancy recognition.17-19 Rates of NTDs by
ethnicity demonstrat that Hispanics have the highest prevalence (4.2 per
10,000 births) than Non-Hispanics. (Non-Hispanic Black or African American:
3.2 per 10,000 births; Non-Hispanic Whites: 2.6 per 10,000 births).20
Objectives: To explore the prevalence rates of multivitamin use during
pregnancy and to find out the predictors of vitamin use using an established
cohort in New Mexico. Methods: This is a cross-sectional analysis which used
data from the “Safety of Medication and Perception of Teratogenicity
iii

(SMART)” study. Patients in the SMART study were recruited from 5 University
of New Mexico affiliated prenatal clinics. Patients were considered vitamin
users if they took vitamins at least 4 times a week. Based on the different time
exposure to vitamins, vitamin use was further categorized into three groups:
pre-conceptional vitamin users, vitamin users after pregnancy recognition, and
vitamin non-users. Chi square and ANOVA were used to identify potential
predictors including sociodemographic characteristics, lifestyle characteristics,
medical and reproductive health, and medication use. For multivariate analysis,
ordinal logistic regression and polychotomous logistic regression model were
used. Results: Most pregnant women (71.9%) in the sample began to take
vitamins regularly after pregnancy recognition. Earlier vitamin use in
pregnancy was significantly associated with pregnancy planning independent
of other maternal characteristics. Education level and health insurance status
revealed a significant interaction with respect to vitamin use. Lastly, almost
one third (32.1%) of women in this study had a history of adverse pregnancy
outcomes and 45.0% of women had at least one medical condition. Vitamin
non-users were more likely to have experience of adverse pregnancy
outcomes in prior pregnancies compared to women who used vitamin after
pregnancy recognition. Implication: This study highlights the importance of
promoting vitamin use in New Mexico in women of childbearing years prior to
conception and in early pregnancy, given the finding that less than one third of
women used vitamins during the pre-conceptional period. Public health
strategies should also include the promotion of pregnancy planning.
Key word: Vitamin, Pregnant women, Predictors, Prevalence, Ordinal Logistic
Regression, Polychotomous Logistic Regression
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CHAPTER I: INTRODUCTION
Background
Multivitamins are considered as a necessary supplement for pregnant
women.21

They

contain

a

wide

range

of

supplements

including

water-soluble/fat soluble vitamins (e.g. vitamin A, vitamin B, folic acid) and
minerals, most of which have been recommended for prenatal use in the
U.S.22,

23

Women can benefit from using prenatal multivitamins during

pregnancy. For instance, the risks of having preterm birth and preeclampsia
can be reduced.24,

25

Prior evidence indicated that prenatal multivitamin

supplementation can provide protective effects against a series of birth defects
including cardiovascular defects,1, 2 limb defects,3-5 orofacial cleft,7, 8 urinary
tract anomalies,4, 6 congenital hydrocephalus,26 respiratory tract defects,26 and
omphalocele.27 In addition, periconceptional use of prenatal multivitamins
containing folic acid is associated with decreased risk for Neural Tube Defects
(NTDs).2, 9-16

Among many birth defects, NTDs, a structural birth defect, are one of the most
severe congenital malformations in human beings.28 NTDs are a series of
malformation of the developing brain and spinal cord, and it occurs when there
is an incomplete closure of the neural tube within a month of fertilization.29
Anencephaly and spina bifida are the most common NTDs, and they affected
around 300,000 newborns worldwide.30 In the U.S., the number of NTD
affected pregnancies decreased after the introduction of food fortification in
1998. A CDC report analyzed data from 23-poplation-based surveillance
systems and comparing the prevalence of NTD before and after folic acid
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fortification (1995-1996 vs. 1999-2000), suggesting that the average annual
number of NTD-affected pregnancies was 3,020, comparing to 4,130 before
food fortification.31 However, the recent national data from 14 states showed
that anencephaly and spina bifida still affected 859 and 1460 babies each year
in the U.S., respectively.32, 33 The causes of NTDs can be either environmental
or genetic, but the causative mechanism of NTDs is still unclear and poorly
studied.28,

34

However, a majority of current clinical studies found that

periconceptional multivitamin supplementation containing folic acid can have a
protective effect against neural tube defects.2, 9-16 In addition, a meta-analysis
summarized the findings and showed that the overall effect of periconceptional
use of multivitamin plus folate was significantly effective in protecting against
NTDs.29

In the U.S., the prevalence of multivitamin use during pregnancy has been
documented by previous studies and ranges from 68.8-78%.19, 35 Unfortunately,
the prevalence of regular prenatal multivitamin use (at least 3 times per week)
is reported 53.8%.36 Although a study using data from the National Maternal
and Infant Health Survey (NMIHS) showed that the prevalence rate of
multivitamin regular use was 82.5% in pregnancy.37 This prevalence combined
mineral use with multivitamin use and therefore might amplify the estimation of
prevalence of multivitamin use in pregnancy.

While the majority of women initiate multivitamin use after pregnancy
recognition, only 24.0% of women reported having ever used multivitamins
during periconceptional period35- the most crucial period for organogenesis.

2

Multivitamin use during the first semester might be higher, but still in sufficient
(29.3%).38 With regard to multivitamin regular use during periconceptional
period, the prevalence of periconceptional multivitamin regular users (at least
3 times per week) was reported around 21.0%.36 Before recognition of
pregnancy, studies showed that only 26% of women reported using
multivitamins regularly (at least 3 times a week).37 Two Centers for Disease
Control and Prevention (CDC) reports using data from Pregnancy Risk
Assessment Monitoring System (PRAMS) suggested that the prevalence of
pre-conception multivitamin use was 23-45.2%.18, 39

Unplanned pregnancies may account for the difference in prevalence rates of
multivitamin use between periconceptional period and after the recognition of
pregnancy.40 Women with unintended pregnancies become aware of their
pregnancies at a later gestational age than women who planned their
pregnancies.41 As a result, the time of multivitamins exposure during
periconceptional period may be delayed for women who did not plan a
pregnancy.

Difference in prevalence of multivitamin use among pregnant women was also
found among different racial groups. Only 25.6% and 67.0% African American
use multivitamins in periconceptional period and later in pregnancy,
respectively. On the other hand, 55.0% and 84% non-Hispanic white mothers
use multivitamins in these two periods.37,

42

For Hispanics, a national

investigation using data from the Behavioral Risk Factor Surveillance System
(BRFSS) showed that 66.4% of Hispanic pregnant women reported having
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ever used multivitamins since pregnancy.19 Data obtained from the National
Birth Defects Prevention study showed that the prevalence of periconceptional
intake of folic acid-containing supplements is only 30% among Hispanics,
which is the lowest comparing to other racial groups (Non-Hispanic White:
66%; Non-Hispanic Black: 39%).43

Some evidences show that Hispanic women might have a high rate of adverse
pregnancy outcome comparing to non-Hispanic white women. Before the
introduction of mandatory food fortification in 1998, it has been documented
that the prevalence of NTD is almost 3 times higher among infants of Hispanic
women than that for non-Hispanic white women.44-46 Although the overall trend
of NTD prevalence has declined since fortification, the prevalence of NTD is
still greater in Hispanics (4.17 per 10,000), comparing to non-Hispanics
(Non-Hispanic Black or African-American: 2.64 per 10,000; Non-Hispanic
Whites: 3.22 per 10,000)20 Also, a CDC report using data from the Pregnancy
Risk Assessment Monitoring System (PRAMS) found that the prevalence of
having a low birth weight infant was higher among Hispanics than
Non-Hispanic white women.47 Moreover, a cross-sectional study used data
from the National Birth Defects Prevention Study and found that foreign-born
Hispanics had a higher risk of delivering babies with spina bifida than US-born
Hispanics, and the higher prevalence of NTDs was also found among recent
immigrants from foreign countries.48 In addition, a low or deficient level of folic
acid are found among Hispanic women because they are more likely to
become pregnant relatively soon after giving birth.49 The national vital statistics

4

reports in 2005 showed that Hispanic women have a higher birth rate and often
had children at an older age.50

The lack of knowledge about benefits of vitamin use among Hispanic women
might at least partially explain the higher prevalence of NTDs in Hispanics
compared to Non-Hispanic Whites and African American women. However,
there are also other factors that might account for a higher prevalence rate.
Environmental exposures might be a contributing factor. For instance,
pesticide exposure might be higher among Hispanic women, especially
women involved in the farm labor, as demonstrated in some prior studies.51 A
population-based

case-control

study

among

Mexican-born

Hispanics

demonstrated that cigarette smoke, including second-hand exposure,
significantly increased risk of NTDs.52 Cultural norms and fatalism could also
be a potential explanation for high prevalence of NTDs at birth. Religious
beliefs, one important component of Hispanic culture norms, make it possible
that Hispanic women are less likely to abort their children regardless of
possible birth defects. Moreover, in fatalistic attitudes among Hispanics, they
might believe that life events are predetermined. Therefore, Hispanic mothers
may be less likely to participate in prenatal screening. As a result, Hispanic
mothers might be more likely to deliver babies with NTDs than Non-Hispanic
mothers.

There is a great need to compare the prevalence of periconceptional and
preconception multivitamin regular use among Hispanics vs. non-Hispanic
Whites, which can help us estimate the difference in the vitamin use between
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Hispanic women and other racial groups. In addition, understanding specific
predictors can identify those Hispanic women who are at risk of not using
prenatal multivitamin. This is important as culturally–sensitive interventions
can be developed and promote early vitamin use in pregnancy among
Hispanic women.
Special Aims
The main purpose of this research is to investigate the prevalence of regular
multivitamin use among different racial/ethnic groups of pregnant women and
to describe the maternal characteristics of regular vitamin users. Specifically,
the following aims are proposed:
Aim 1) To determine the differences in the prevalence of multivitamin regular
use (at least 4 times per week) in preconception period (at least one month
before last menstrual period) and in pregnancy (after pregnancy recognition)
between Hispanic and non-Hispanic pregnant women.

Hypothesis 1: we hypothesize that the prevalence of preconception
multivitamin regular use will be lower in Hispanic than in Non-Hispanic women.

Aim 2) To examine the predictors (e.g. ethnicity, education level, insurance
status, age, marital status, pregnancy intention, smoking status, alcohol use,
recreational drug use, parity, gravidity, a family history of birth defects, the use
of prescription medications) of not preconception multivitamin regular use from
an established cohort of pregnant women in New Mexico.

6

Hypothesis 2: we hypothesize that pregnant women who did not use
multivitamins in preconception period are more likely to be Hispanics, less
educated, younger, uninsured, unmarried, had an unintended pregnancy
intention, are foreign born, multiparous, multigravida, speaking Spanish,
current smokers, periconceptional binge drinker, recreational drug user,
without a family history of birth defects, and use less than 2 kinds of
prescription medications.

7

CHAPTER II: LITERATURE REVIEW
The literature review for this study is organized into following sections: (1) the
benefit of using multivitamin during pregnancy and periconceptional period; (2)
the prevalence of multivitamin use among pregnant women; 3) predictors of
multivitamin use; 4) definition of multivitamin use in periconceptional period
and early pregnancy in different studies; 5) a review of economic evaluations
on food fortification and folic acid use.

The Benefit of Multivitamin Use in Pregnancy
We systematically reviewed the benefits of multivitamin supplementation use
in

pregnancy

and

summarized

contents

as

following

categories:

cardiovascular defects, limb defects, urinary defects, orofacial defects, neural
tube defects, and other defects and adverse perinatal adverse outcomes.

Cardiovascular Defects
There are many types of cardiovascular defects, such as transposition of great
arteries (TGA), hypoplastic left heart syndrome (HLHS), atrioventricular septal
defect (ASD). In the U.S., it has been estimated that TGA, HLHS, and ASD
occurred 1 cases in 3,333 births, 1 case in 2,122 births, and 1 case in 4,344
births.32 It also accounts for a major cause of infant deaths.53 Some studies
showed a significant association between the use of multivitamin containing
folic acid in pregnancy and occurrence of cardiovascular defects of infants.1, 2
One randomized clinical trial from Hungary found that the risk of congenital
cardiovascular malformations (e.g. ventricular septal defect, aortic stenosis,
patent ductus arteriosus) was significantly lower among women daily used
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periconceptional multivitamins with 0.8 mg folic acid at least one month before
conception.2 A population-based case-control study from the U.S. also
confirmed that the periconceptional multivitamin use (any multivitamin use 3
month before to 3 months after conception) can reduce the risk of congenital
heat defects (OR=0.60-0.97).1 In contrast, a case-control study collected data
from Slone Epidemiology Unit Birth defects Study, tested a series of selected
birth defects but did not find a significant association between preconceptional
multivitamin supplementation (2 month before last menstrual period) and risks
of

conotruncal

defects.4

This

result

is

consistent

with

the

Baltimore-Washington Infant Study (BWIS), a large case-control study, which
showed no protective effect of multivitamin use during the first 5 weeks of
gestation.54 These two contradicting results may be due to differential maternal
recall of multivitamin use in the Slone Epidemiology Study or the fact that the
interview in BWIS study was conducted prospectively before the infant’s
birthday while other studies respectively interviewed mothers after the delivery
of infants.

Limb Defects
There are two major types of limb defects: upper limb (e.g. arms) defects and
lower limb (e.g. leg) defects. There are approximately 1,500 babied in the U.S.
born with upper limb defects and 750 with lower limb defects for each year.33
Periconceptional use of multivitamin can also provide a protective effect
against limb defects. A few case-control studies suggested that women who
used multivitamin periconceptionally (from 3 months before conception until 3
months after pregnancy) could significantly reduce (OR=0.3-0.64) the risk of
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developing infants with limb defects.3,

5

One of the case-control studies

specified that this protective effect was significant in transverse limb defects
but not in other limb defects, such as preaxial and postaxial deficiencies.5 In
addition, a meta-analysis conducted by Canada showed that use of
multivitamin supplements before during the first trimester of pregnancy
provided consistent protection against

limb defects (OR=0.48, 95%

CI=0.30-0.76).55 However, a case-control study conducted in Boston,
Philadelphia, and Toronto during 1993-1996 did not find a significant reduction
in limb defects among women who used multivitamins regularly before and in
the first trimester use4 The reason might be due to non-population based
subject ascertainment and selection bias.

Urinary Tract Anomalies
In the United States, congenital malformation of the genitourinary system
caused 518 deaths per 100,000 live infant per year.56 Several studies have
been done and demonstrated that periconceptional multivitamin use could
significantly reduce the risk of urinary tract anomalies, such as rental agenesis,
obstructive congenital abnormalities of the urinary system.4, 6, 57 Of note, the
risk reduction become smaller when multivitamin use was limited to the second
or third trimester, which was reported by a case-control study, using data from
the Slone Epidemiology Unit Birth defects Study.4 A randomized double-blind
controlled trial from Hungary was conducted and found that the daily
periconceptional use (at least one month before conception and at least until
the date of the second missed menstrual period) of multivitamin containing 0.8
mg of folic acid can significantly reduce the rate of urinary tract abnormalities.57
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However, the same author did not find this association in a follow up
case-control study.2 The protective effect of periconceptional multivitamin use
might be attenuated due to potential selection bias.

Orofacial Clefts
cleft lip with or without cleft palate (CLP) and cleft palate alone (CP) are two
kinds of main orofacial clefts, and it has been reported that CLP and CP
affected approximately 1 in 941-1000 and 1 in 1574-2500 infants,
respectively.32,

58

Mixed findings have been found with regarding to the

protective effect of multivitamin use and occurrence of orofacial clefts. Some
studies reported that the risk reduction for CLP but not for not in CP among
women who used multivitamins regularly during periconceptional period (3
months before through 3 months after conception),10, 58

while other studies

found a reduction for CP but not for CLP.59 In addition, one case-control study
reported that the greatest reduction in the risk of CLP occurred with
periconceptional multivitamin use (28 days before through 28 days after
conception).4 Also, there are other studies showing that the risks of both CP
and CLP can be reduced by using multivitamin periconceptionally (one month
before through two months after conception).60 On the contrary, there is one
case-control study which did not find any significant associations between the
periconceptional multivitamin supplementation containing folic acid and
reducing risk of CP or CLP.61 Recall bias might be a problem in this study
when women were asked to report multivitamin use that occurred up to more
than one year before the time of interview.
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NTD (Neural tube defects)
NTD is a severe structural defect due to the incomplete closure of the neural
tube within a month of fertilization.29 The most common types of NTD are
anencephaly and spina bifida.

Infants born with anencephaly usually die

within the first few hours/days after delivery, while a majority of infants born
with spina bifida grow to adulthood exhibiting only physical disability but having
normal neurobehavioral development.22 The medical costs for the first year of
life for a child with spina bifida was $52,415.62 It is still unclear of the causative
mechanism, but there are extensive studies which suggested that the use of
periconceptional multivitamin supplementation (from 3 months before and
through 3 months after conception) can have a protective effect against
NTDs.2,

9-16

A randomized double-blind prevention trial was conducted in 7

countries and find that periconceptional multivitamin containing folic acid (4 mg
folic acid per day) can reduce recurrence risk of NTDs, but whether lower
doses had same protective effect was unknown.9 Another randomized trial
suggested that a daily dosage of 0.36 mg of folic acid could still be as
protective as a daily dosage of 4 mg of folic acid

15

. Moreover, one

case-control study from California found that there was a significant reduction
associated with periconceptional multivitamin use (from 3 months before and
through 3 months after conception) for NTD.10 Due to different study design
and multivitamin supplementation measurement, some studies, however, did
not find a protective effect of periconceptional multivitamin supplementation on
preventing neural tube defects.14, 63-65
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Other Defects and Adverse Perinatal Outcomes
There are a number of studies which evaluated other birth defects and adverse
pregnancy outcomes. A population-based case-control study found that
periconceptional use (3 months before pregnancy through the first trimester of
pregnancy) of multivitamin could reduce the risk for omphalocele, an
abdominal wall defect.66 However, the precision of this study was limited by
small sample size in case-infants, which only 72 cases were ascertained. A
population-based Atlantic Birth Defects Case-Control study examined the
associations of periconceptional multivitamin use (from 3 months before
pregnancy through the first 3 months of pregnancy) and respiratory tract
defects, pyloric stenosis, anal atresia, but none of them yielded a significant
result.26

The association of preterm birth and multivitamin use is also studied.
Case-control studies suggested that its risk could be reduced approximately
1.6-2 folds with multivitamin supplement use during pregnancy.38,

67

Surprisingly, a case-control study reported that multivitamin use during the
third trimester was increased risk of preterm birth.68 The interpretation of this
result, however, needs to be caution, and the mechanism is unclear.

The association between adverse pregnancy outcome (miscarriage, ectopic
pregnancy, and stillbirth) and the use of multivitamin containing folic acid
during periconceptional period was also studied, but none of them was
reported

significantly

associated

with

supplementation use.9, 69, 70
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periconceptional

multivitamin

Preeclampsia is considered to a pregnancy-related disorder, and it remains a
significant health problem in obstetric population. A prospective cohort study
was designed to detect factors of preeclampsia in the United States, and the
results showed that the periconceptional multivitamin use was associated with
45% of reduction in preeclampsia risk comparing to nonusers.71 Another study
found that regular multivitamin use in the periconceptional period was
significantly

associated

with

reduced

risk

of

preeclampsia

among

normal-weight women.24 However, more studies need to be done in this area
in order to further confirm this result.

In addition to preeclampsia, periconceptional multivitamin supplementation
(not specifically defined) can also significantly reduce the incidence of
pregnancy-induced vertigo, nausea, and vomiting, which reported by a
randomized placebo-controlled trial.72

The Prevalence of Multivitamin Use
Prevalence of Multivitamin Use Anytime in Pregnancy
There is a variation in the prevalence of using multivitamins during pregnancy.
In the United States, it was previously reported in 1998 that 53.8% of women
from the National Maternal and Infant Health Survey reported using either
multivitamin and minerals 3 times per week after pregnancy recognition.36
After the introduction of mandatory folic acid fortification, the prevalence rate
went up and ranges from 68.8-78% in 2009.19, 35
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In Europe, the prevalence of multivitamin use during pregnancy was reported
as 76.2% in Portugal, which was highest comparing to other countries in
Europe.73 Unfortunately, the comparability of the data on the prevalence of
multivitamin use was undermined by combining minerals use with
multivitamins. Besides, there were another two studies estimating prevalence
by combining multivitamins and minerals. One study suggested that 30.8% of
participants using multivitamins minerals during pregnancy,74 while another
study broken down the prevalence rate and specified it into three trimesters
periods, revealing that 23.3%, 14.1%, and 18.6% of women used
multivitamin-mineral during the first trimester, second semester, and third
trimester, respectively.68 In addition, in Australia, the prevalence rates of
multivitamin use during pregnancy were between 18-35%75, 76. In Brazil, the
prevalence of multivitamin use was 14% as reported.77

Prevalence of Multivitamin Use in Periconceptional Period
In the U.S., the prevalence of periconceptional multivitamin (begin before
pregnancy and continue to use in pregnancy) was reported as 21-23.8%.35, 36
There were also studies which attempted to specify the time frame of
multivitamin exposure during periconceptional period. A Pregnancy Exposure
and Preeclampsia Prevention Study (PEPPS) found that 47% of women took
multivitamins/prenatal vitamin at least once per week during periconceptional
period (from 3 months before pregnancy through the first 3 months of
pregnancy).78 Recall bias might impact on the prevalence rate estimation in
this study while women were asked to remember multivitamin use 3 months
before pregnancy. A National Birth Defects Prevention (NBDP) Study further
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examined periconceptional multivitamin use (one month before LMP and
through the month after LMP) and pregnancy intention and found that 35.7% of
women who did not plan for the pregnancy used periconceptional multivitamin,
while the prevalence of periconceptional multivitamin use among women who
had a pregnancy intention was reported as 59%.79

In Canada, a

cross-sectional analysis conducted in Toronto Hospital and the Mount Sinai
Hospital found that only 28% of women reported using multivitamin
supplementation containing acid during periconceptional period (at least 4
weeks prior to conception until 8 weeks after conception).80 Additionally,
preconception multivitamin use-multivitamin use during the month before
pregnancy- was also studied. Data from PRAMS showed that the prevalence
of preconception multivitamin regular users (≥ at least 4 times per week) was
23.0-43.6%.18, 39, 47 81

In Europe, a study from Demark using data from Danish National Birth Cohort
and found that 65% of women had used multivitamins in periconceptional
period (4 weeks before LMP through the 8 weeks after LMP).24 The high
prevalence is because of the fact that Caucasian women accounted for most
of this population in Denmark and they were more prone to use
periconceptional multivitamins. To the contrast, two other studies, one from
Sweden using women who attended antenatal care units and another from
Norway using Medical Birth Registry, found that 15.9-19% of women used
vitamin during periconceptional period (not specifically defined: before
pregnancy

and during pregnancy).49,

82

Regarding

to

preconception

multivitamin use, one study from Hungary reported that the prevalence of
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preconception multivitamin regular use was 43.8%.83 However, all the data on
multivitamin use were based on self-reports from voluntary participants, which
might have a potential selection bias.

In Australia, a cross-sectional analysis showed that 12.3% of women had used
multivitamins during periconceptional period (3 months prior to pregnancy and
during pregnancy).76 Another cross-sectional survey from Australia found that
21.8% of women had used multivitamin during periconceptional period (not
specifically defined: before and during pregnancy).75

Multivitamins vs. Prenatal Vitamins
Most studies assumed that prenatal vitamins and multivitamins are similar in
contents.

Information of multivitamins and prenatal vitamins in other studies

was mixed, and multivitamin users were identified if women reported having
taken multivitamin or prenatal vitamins.35, 38, 47, 78, 79, 81 Therefore, we cannot
separately specify the prevalence of prenatal vitamin use from these results. It
is of note that there is one study from U.S. that investigated the prevalence of
prenatal vitamin use among women at rural outreach clinics and reported that
92% of women had used prenatal vitamins during pregnancy.84 For most of
other studies, the use of prenatal vitamins was not separately specified to
investigate the prevalence.

Predictors of Multivitamin Use
Studies identified examined the maternal characteristics of multivitamin users.
Prenatal multivitamin users (use multivitamin anytime during pregnancy) were
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more likely to be White42, 47, better educated,37, 42, 78, 85 older,37, 42, 77, 82 married
or cohabiting with a partner,19, 37, 42, 78, 82 be primiparous,77, 82 have a higher
income,19, 37, 42, 47 pregnancy intention,79 and private health insurance.47 Similar
to multivitamin users during pregnancy, periconceptional multivitamin users
are those who were non-smokers,42, 82, 86 married,42, 78, 82, 85, 86 older,42, 82, 86
have a high socioeconomics status,42,
primiparous,75,

80, 82

86

better educated,42,

78,

85,

86

normal BMI,78 However, a population-based survey

initiated by the Medical Birth Registry and the National Council on Nutrition
and Physical Activity from Norway reported periconceptional multivitamin
users were tended to be younger.85 With regard to preconception, multivitamin
use are more likely to be white,47 older,39,
pregnancy,47,

86

47

more educated,39 intended

and have private health insurance.47 To the contrary, the

preconception non-multivitamin users are more likely to be Black,81 younger,81
less educated,39 Medicaid recipients.39, 81

Definition of Multivitamin Use in Periconceptional Period and Early Pregnancy
Regular Use vs. Non-regular Use
Multivitamin use is assessed in various ways. First, women are often identified
as multivitamin users if they use multivitamins at the time of assessment or
reported having ever used multivitamins in pregnancy.19, 24, 35, 38, 49, 76, 77, 79, 82, 84
However, this assessment does not take into consideration the frequency and
duration of multivitamin use, and this could lead to overestimation of
multivitamin regular use. It could be possible that women who had just used
multivitamin once were also regarded as multivitamin users. There were some
studies estimating multivitamin use among regular users.36, 37, 42, 74, 78, 85 The
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change in the definition from multivitamin users to multivitamin regular users
did not cause large variation in prevalence of using multivitamins during
pregnancy. In the U.S., the prevalence of using multivitamins during
pregnancy was reported between 78.0% and 82.5%.35,

37

Regarding to the

prevalence of periconceptional multivitamin use in the U.S., one study reported
that

23.8%

of

women

periconceptional period,31

reported

having

used

multivitamin

during

while another study suggested that 21.0% of

women reported regularly using multivitamins (3 days a week) during
periconceptional period.36

Prescription vs. OTC Multivitamins
The main difference between prescription and OTC multivitamins is the
amount of folic acid: while OTC multivitamins contain 400 micrograms dose,
prescription multivitamins have 1000 micrograms. A majority of studies asked
women to report their multivitamin use but did not further asked women
whether the multivitamins they took was prescription or OTC multivitamins.
Although some studies collected information of brand of multivitamin
supplementations, it is often not reported and still unclear about prescription
multivitamin as well as OTC multivitamin use among pregnant women. A few
of studies, however, investigated prescription and OTC multivitamins among
multivitamin users. One study from U.S. investigated women at rural outreach
clinics and reported that 92% of women had used prescription prenatal
vitamins during pregnancy, while 10.9% of women had used OTC
multivitamins.84
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Multivitamin vs. Single Vitamin
The use of single vitamin (e.g. vitamin A, vitamin B, vitamin C, vitamin D,
vitamin E, folic acid) along with multivitamin use was studied. It seems that a
small proportion of women who took multivitamin took additional single
vitamins: a population-based study from UK assessed frequency and amount
of all single vitamins during pregnancy including vitamin A, vitamin C, and
vitamin E, all of which were below 5%.

68

Contrary to other single vitamins, a

large number of women who took multivitamin also took additional folic acid
supplementations during pregnancy: it was reported that the prevalence of
taking folic acid was between 71.4-78.7%.68 75

The Timing of Measuring Multivitamin Exposure among Pregnant Women
The

time

frames

for

multivitamin

exposure

during

pregnancy

and

periconceptional period were defined differently. For pregnancy, multivitamin
exposure was usually measured after women realized they were pregnant or
used the last menstrual period as the beginning time point of pregnancy. There
is a time gap between the last menstrual period and women’s recognitions of
pregnancies, and women may not realize they were pregnant even the fetus
was developing. A population-based study combined these two time points by
asking women if they used any multivitamins since their recognitions of
pregnancies or last period menstrual.35

Periconceptional period in studies is often defined 28 days prior to the last
menstrual period to after 28 days after the last menstrual period.42 Some
studies expanded the endpoint of periconceptional period to 8 weeks after last
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menstrual period.24, 49 In addition, some studies did not define an exact time for
periconceptional period but defined periconceptional multivitamin users as
women who reported having used multivitamin before LMP and continued in
pregnancy.35 36

Economic evaluations on food fortification and folic acid use
Some studies evaluating the benefits of folic acid fortification in food in the U.S,
showed that it was associated with an annual economic benefit of $312- $425
millions and that the cost savings (net reduction in direct costs) ranged from
$88 to $145 millions per year.87 Another cost-effectiveness analysis from the
U.S. analyzed folic acid fortification policy and found that it could achieve
$266,649 per QALY gains.88 However, this study did not focus on pregnant
women and NTDs. The outcomes in this study included myocardial infarctions
and color cancer for males.

In the Netherlands, a cost-effectiveness analysis conducted from a societal
perspective found periconceptional use of folic acid supplementation was
cost-effective (€1800-4500 per QALYS).89 However, this study did not include
productivity loss as a component in their cost estimation. There is another
pharmacoeconomic

study

from

the

Netherlands

which conducted a

cost-effectiveness analysis to evaluate the folic acid food fortification and
prevention of NTDs from a societal perspective. That study found that
fortification of bulk food with 140μg folic acid per 100g results in cost savings if
the cost of enrichment does not exceed €5.5 million.90 However, the result of
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this study might not be comparable, because the cost estimation was
estimated under a different health care market and health care system.
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CHAPTER III: RESEARCH DESIGN
Study Population
This is a cross-sectional study using data from the “Safety of Medications and
Perception of Teratogenicity (SMART)” study. SMART is a prospective
multi-clinics study conducted at the University of New Mexico (UNM). Eligible
participants were women who aged 18 or older and attended UNM-affiliated
prenatal care clinics (UNMH Fetal Monitoring Clinics, Triage, General
Obstetric/Gynaecological, Satellite Clinic-West Mesa, Satellite Clinic-South
Broadway, Satellite Clinic-North Valley) in Albuquerque, NM, during
2008-2009. A written informed consent in English or Spanish was obtained
before each interview. If women agreed to participate, a semi-structured
interview was administrated by a trained bi-lingual interviewer fluent in English
and Spanish in a private setting at the clinics. If women did not want to
participate, they would be asked to give reasons for non-participation.
Institutional Review Board (IRB) approval for this study was obtained from the
UNM Research Review Committee (HRRC).

On an initially screening, 493 pregnant women who were consecutively
chosen from UNM main hospital and satellite clinics were offered participation
in the study. Among those, 404 women enrolled in SMART study (response
rate=81.5%). The major reasons for non-participation were the time constrains
and lack of interest in the study. For the purpose of this study, women who did
not report their multivitamin use were excluded (n=2). Therefore, 402 women
were included for the present analysis.
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Measurements
Sociodemographic Characteristics
Sociodemographic characteristics, including maternal age (continuous),
marital status (single/never married, married/living with spouse, not married
but living with partner, separated from spouse, divorced, widowed), race (white
Non-Hispanic, white Hispanic, black or African American, American Indian or
Alaskan native, Asian or Asian American or Pacific Islander, some other group,
prefer not to report), ethnicity (Hispanic/Latino/Spanish descent, other ethnical
groups), level of education (less than high school graduate, high school
education or GED, some college or vocational school, college degree,
master/doctorate or professional degree), health insurance status (no
insurance, employer-based insurance, self-purchased insurance, Medicaid,
other public insurances), place of born (U.S. born, foreign born), years of
staying in U.S for immigrants, language predominantly spoken at home
(English, Spanish, some other language) were ascertained. In addition, if
women described themselves as American Indian or Alaskan Native, they
were further asked to specify whether they can identify a specific tribe or
pueblo. Women were also asked whether their health insurance covered
prescription drug or not. For women who reported having other public health
insurances, they would be asked to specify whether it is Indian Health Service,
Veteran Affair (VA), First Choice, UNM/UNM Care, or other types.

Lifestyle Characteristics
Interviewer asked participants to report their lifestyle characteristics including
smoking, alcohol use, and illicit drug use. We firstly asked women whether
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they smoked cigarettes or used tobacco at the time of the interview. If they
answered “yes”, the number of cigarettes in a day was recorded. Otherwise,
we asked them whether they have ever smoked more than 100 cigarettes and
whether they stopped before or after recognition of pregnancy.

Regarding alcohol use, we asked women whether they have ever used alcohol.
If women answered “yes”, the interview would ask them to specify the number
drinks typically she feels the first effect of alcohol and the number of drinks she
can hold before passing out of falling asleep. We ascertained periconceptional
binge drinker by asking women how many times participants drank four or
more drinks during a month around the LMP. In addition, the standardized
TWEAK (Tolerance, Worried, Eye-opener, Amnesia, Kut down) with “hold” and
“high” versions of the questionnaire was administrated.91-93 The difference
between the two versions is the cutoff point of “Tolerance”. In the “hold”
version, tolerance was ascertained if a woman drank more than six drinks she
could tolerate, while the cutoff point is three in the “high” version. For “Worried,
we asked whether the woman’s close friends or relatives worry or complain
about her drinking; for “Eye-opener”, we asked a woman whether she has
taken a drink first thing in the morning to get herself going; for “Amnesia”, we
asked a woman whether her friend or family member tell her about things she
said or did while she was drinking that she could not remember; for “Kut down”,
we asked a woman whether she felt a need to cut down on her drinking. To
calculate TWEAK score, we gave each woman one point per question if they
answered yes to a question regarding using alcohol as an eye opener in the
morning, memory loss, or cutting down on alcohol. Two points would be given
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to a woman if she responded yes to the question regarding “Worried” or she
meets the cutoff point of “Tolerance”.

Additionally, the interviewer asked women their recreational drug use including
marijuana/hashish, heroin, cocaine/crack, inhalants, methamphetamines,
other recreational drugs. For each type of recreational drug, recreational drug
users were asked to specify the exposure time, whether before pregnancy or
one month prior to LMP or during the current pregnancy. Women were also
asked whether they had taken methadone treatment and whether they had
completed treatment before pregnancy or still undergone treatment during
pregnancy. Questions about recreational drug use were introduced in January
2009. Therefore, information on recreational use for women who were
recruited in 2008 was missing.

Medical and Reproductive Health
Information on medical and reproductive health was queried and confirmed by
electronic medical records review: pre-pregnant weigh (pounds), pre-pregnant
height (feet), gestational age at the time of interview, presence of medical
conditions (if yes, women would be asked to specify the following medical
conditions: hypertension, depression, diabetes, anxiety, seizure disorder,
migraine headaches, thyroid disorder, rheumatoid arthritis, asthma or allergies,
heart disease, cancer, hepatitis).

Questions about reproductive health included pregnancy planning (i.e., “Did
you plan to get pregnant with this child?” The answers consist of three options:
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“Yes”; “No, not now”; “No, not at any time”). At the beginning of this study, the
first 42 study participants were not asked about their pregnancy planning, and
there were additional 8 women who did report their pregnancy planning during
the interview.

Other questions regarding reproductive health included a history of
miscarriage, stillbirth, pregnancy termination, and ectopic pregnancy in a prior
pregnancy, gravidity (number of pregnancies including current pregnancy),
parity (number of live-born children), the date of the last menstrual period, a
family history of birth defects. For a family history of birth defects, women
would be firstly asked whether she or her members of immediate family or the
immediate family of her baby’s father had any babies with birth defects. If such
history was reported, participants were asked to specify the following birth
defects: Down syndrome, cleft lip or palate, neural tube defects, cystic fibrosis,
heart defect, or other defects. We also investigated the presence of
complications for current pregnancy including bleeding, high blood pressure,
diabetes, and other complication and asked women whether they had morning
sickness during the current pregnancy.

Vitamin and Dietary Supplement Use
All enrolled women were asked whether they had taken any vitamin, including
multivitamin or single vitamin, prescription or over-the-count (OTC) vitamin, at
least 4 times a week since they became pregnant. Also, women who reported
using single vitamin or multivitamin were asked to specify brand name of
vitamin and the time they had started vitamin use. Periconceptional vitamin
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use was ascertained by asking women if they had taken vitamin at least 4
times per week during the month around their LMP.

Regarding dietary supplements, we asked a woman whether she took dietary
supplements (including iron supplements) or herbal products on a regular
basis since her last menstrual period. If she response “Yes”, we further asked
her to specify the type of herbal products, the frequency of dietary supplement
use, and reasons for taking it.

Medication Use
The use of medications during pregnancy was also ascertained. To begin with,
we asked a woman whether she discussed safety of medications in pregnancy
with any health care provider (physician, nurse-midwife, physician assistant, or
pharmacist). Then, we asked women about the use of OTC and prescription
medications since LMP. For OTC medication, following OTC medications were
provided:

acetaminophen,

aspirin,

ibuprofen,

ketoprofen,

naproxen,

chlorpheniramine, benadryl, pseudoephedrine, kaopectate/pepto bismiol.
Questions about prescription medications included pain/fever medication,
nasal decongestants/allergy/cough medications, antidiarrheal, medication, and
heart burn/dyspersia/antiemetic/laxative medications. For the attitudes of each
medication use, we provided a five-point Likert type scale was used to assess
the perception of teratogenicity.

In additional to medication use, we also investigated vaccine exposure since
LMP (e.g. flu vaccine, other vaccine) and asked women to specify the types of

28

cravings or non-food item/strange good they took. Women were also asked
about the use of fertility medications with current pregnancy (e.g. Clomid,
Metrodin, Fertinex, or Pergonal).

Perinatal Outcomes
Perinatal data were abstracted from electronic medical records including
pregnancy outcomes, i.e. live-born infant, spontaneous abortion (<20
gestational weeks), stillbirth (≥20 gestational weeks), termination, lost to
follow-up. Date of delivery and gestational age at the end of pregnancy were
also

recoded.

Type

of

delivery

(vaginal-vertex,

vaginal-breech,

vaginal-transverse, cesarian section-primary, cesarian section-repeat) was
obtained from medical records. Maternal complications in pregnancy included
preeclampsia, pregnancy induced hypertension, oligohydramnios, infection or
fever at delivery, gestational diabetes, and others, all of which were recorded
in this database. For the live-born children, we recorded gender of the infant,
birth weight (grams), birth length (centimeters), and birth head circumference
(centimeters). In addition, the database also captured the neonatal
complications (respiratory distress, hypoglycemia, tachypnea, bradycardia,
sepsis, and others), diagnosis of major structural anomaly, the number of days
for infant stay in hospital, and diagnosis of any abnormalities/conditions in the
neonatal period.

Data Modifications
A multivitamin regular user was identified if a woman reported having taken
vitamins at least 4 times per week. Based on the timing of the vitamin
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exposure, we further categorized women into three study groups: 1)
pre-conceptional vitamin regular users (women who reported having taken
vitamins ≥4 times per week at least one month before their LMP); 2) vitamin
regular users after pregnancy recognition (women who reported beginning to
take vitamins or single vitamin at least 4 times per week since they became
pregnant); 3) vitamin non-users (women who reported not having taken any
vitamins before their last menstrual periods or since they became pregnant).

Potential predictors were identified from previous studies. We categorized
predictors

in the following manner: maternal age was categorized into

categories (≥21 yrs, 21-30 yrs, >30 yrs); level of education was categorized
into three levels (high school education or less, some college or vocational
school, college degree or higher); marital status was recategorized into three
categories

(single/never

married,

married/living

with

partner,

separated/divorced/widowed); for health insurance status, we made three
categories (uninsured, employer-based or self-purchased insurance, Medicaid
or other public insurance); language speaking was dichotomized as “Spanish”
and “English and other language” (there were 6 women who speak other
languages other than English and Spanish); for body mass index, the reported
prepregnancy height and weight were used to estimate the BMI (kg/m2) and
then BMI was dichotomized as obese (BMI≥30) and nonobese (BMI<30).

For gravidity and parity, they were dichotomized into two categories
(primigravida if gravidty=1 vs. multigravida if gravidity≥2) and (primiparous if
parity=0 vs. multiparous if parity≥1), respectively. A woman was identified to

30

have a history of adverse pregnancy outcome if she reported having
experienced

miscarriage,

stillborn,

pregnancy

termination,

or

ectopic

pregnancy in previous pregnancies. For pregnancy planning, a woman was
considered to have a planned pregnancy if she answered “yes” to the question
“Did you plan to get pregnant with this child”, while a woman was regarded not
having a planned pregnancy if she answered “no, not now” or “no, not at any
time”.

For the family history of birth defects, a woman was identified to have a family
history of birth defects if she reported at least one of the following birth defects
in her family: Down syndrome, cleft lip or palate, NTD, cystic fibrosis, heart
defect, or other defects. For BMI, we recoded it as a categorized variable.
Women were classified as obese if BMI equal or larger than 30 or nonobese if
BMI is smaller than 30.

For smoking, we categorized women into three groups: women who smoked
less than 100 cigarettes in a lifetime and did not currently smoke were
identified as non-smokers; women who smoked 100 or more cigarettes in a
lifetime but stopped smoking before pregnancy recognition were identified as a
former smoker who quit before pregnancy recognition; women who currently
smoked or who smoked ≥100 cigarettes or more than 100 cigarettes in a
lifetime but stopped cigarettes after pregnancy recognition were identified as
smokers during pregnancy. For alcohol use, periconceptional binge drinkers
were identified if women have drunk four or more on one occasion during a
month around their LMP. For recreational drug use, women were identified as
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recreational drug users if they reported using any of following recreational
drugs one month prior to LMP or during pregnancy: marijuana, heroin/hashish,
cocaine/crack, inhalant, methamphetamines, or other recreational drugs. In
addition, we also investigated prescription medications use during pregnancy
and categorized pill burdens as follow: no prescription medications at all, 1-2
prescription medications, more than 2 prescription medications.

Statistical Approaches
SAS 9.2 (Cary, NC) was used for all analysis. A descriptive statistics were
performed to describe the maternal characteristics in the entire population.
Also, the prevalence of vitamin use in each study group was estimated. For
vitamin users, we further specified the type of vitamin whether it is OTC or
prescription vitamins. The most common brands of vitamins were determined
based on women’s self reported information. The number of days of vitamin
use per week was additionally calculated. For women who began to take
vitamins after pregnancy recognition, the beginning gestational age of regular
vitamin use was measured using the date of last menstrual period as a starting
time point.

The distribution of maternal characteristics among study groups was
compared by using chi square test for categorized variables and ANOVA for
continuous variables. All the significant predictors (p<0.2) were then entered
into a multivariate ordinal logistic regression model to determine the
association between vitamin use and maternal characteristics after adjusting
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for confounders. Cumulative odds ratio with 95% Confidence intervals were
constructed.

In ordinal logistic regression, we treated the three study groups as categorical
under the assumption that there is a natural ordering across different vitamin
groups. Therefore, the analysis built a set of cumulative logits to interpret the
outcome (vitamin use). In total, two logits were developed as follow: Group 1
versus (Group 2 and Group 3), (Group 1 and Group 2) versus Group 3. The
final model was examined by performing a chi square score test in order to
check the proportional odds assumption. If the assumption is violated, then an
alternative model, polychotmous logistic regression, would be used.

A polychotomous logistic regression model is an extension of dichotomous
logistic regression model when there are more than two categories in the
dependent variable. Unlike an ordinal logistic regression model, the dependent
variable is treated as a nominal and cannot be arranged in any meaningful
natural ordering. In this case, the interest outcome measure in this analysis is
the vitamin use in different time of pregnancy: pre-conceptional vitamin users,
vitamin users after pregnancy recognition, and non-users. Therefore, a
multinomial

model

was

introduced

to

determine

whether

maternal

characteristics differed across three study groups. We did not use a series of
binary models because this approach will give less statistical power to the
results and higher values of standard error.
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In this model, vitamin regular users after pregnancy recognition were the
reference group. The rational of choosing this group as a reference group is
that it this group has the largest frequency of cases and it makes the greatest
clinical sense. Based on the reference group, there were two multinomial logits
for polychotomous logistic regression: pre-conceptional vitamin users relative
to vitamin users after pregnancy recognition and non-users relative to vitamin
users after pregnancy recognition. For each logit, odd ratios and 95%
confidence intervals (CI) of each predictor were estimated from the regression
parameters and their standard errors.

Additional analysis was conducted by using ordinal logistic regression and
polychotomous logistic regression with vitamin use as the response variable in
order to examine interaction terms between different predictors, including
ethnicity and race, ethnicity and place of birth, ethnicity and language speaking,
race and language speaking, race and place of birth, place of birth and
language speaking, education and health insurance status, education and
pregnancy plan. Significant interaction terms would then be involved for the
multivariate analysis.

Power Calculation
The power calculation for this study was done in PASS 11 Software (Kaysville,
Utah) for comparing two independent proportions. For this calculation, we set
the alpha value (the probability of rejecting a true null hypothesis) as 0.05 and
0.2 for beta (the probability of accepting a false null hypothesis). Sample
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allocation ratio was set as three, which is approximately the ratio between
group 1 and group 2 in the present analysis.

Estimations of the required total sample size were based on previously
reported prevalence of pre-conception multivitamin users and prevalence of
multivitamin users during pregnancy. In reference to the former prevalence,
data from PRAMS (Pregnancy Risk Assessment Monitoring System), the
prevalence of preconception vitamin use (P1) is 23.0-43.6% in the U.S.18, 39, 47
81

For the prevalence of regular multivitamin users during pregnancy, the

prevalence was previously estimated to be 68.8-78.0%.19,
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Therefore, we

assume that the difference in the proportion of multivitamin use between the
study groups would be between 20% and 60%. As presented in Table 3.1, the
required total sample size might vary from 24 to 225 depending of the
difference in prevalence between study groups. In sum, a total sample size of
24-225 subjects will achieve more than 80% power to defect a difference
between the effect sizes of 20-60% using the two-sided Z test at an alpha level
0.05. In this present analysis, a sample of 402 subjects will be sufficient and
can achieve a power that more than 80%. To detect 20% difference, a group
sample sizes of 252 could achieve 80% power.
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CHAPTER IV: RESULTS
Description of the Study Population
Maternal characteristics of the total population were summarized in Table 4.1.
The study population included 80.4% of Hispanics, 6.7% American Indian or
Alaskan Native, and 5.7% Black or African American women. In terms of other
demographic characteristics, a majority of women were immigrants (59.6%),
identified Spanish as their primary language (60.7%), were married or living
with a partner (71.6%), reported education less than high school (35.1%), and
did not have any health insurance (48.8%). Additional analysis assessed the
association between insurance status and ethnicity. Results of this analysis
indicate a statistically significant association (p<0.01). Among women without
health insurance, 98.5% of women were Hispanics and 1.5% of women were
Non-Hispanics. Among women with public health insurance, more than half of
participants (66.8%) were Hispanic women. For women have private insurance,
the difference in ethnic distribution was small (Hispanic women, 55.1%;
Non-Hispanic women, 44.9%). Of note, even though there more than half of
women in this sample did not have any health insurance, all participants
received free prenatal care through the UNM clinics.

The average gestational age for women to initiate prenatal care was 8.5±4.4
weeks after the last menstrual period. Most of the women (89.4%) received
prenatal care in their first trimester (1-11 weeks after LMP), and 10.3% of
women initiated prenatal care during the second trimester (12-24 weeks after
LMP). There is one woman who reported starting prenatal care 29 gestational
weeks. There were no differences in the mean gestational age at which
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prenatal care was initiated between Hispanic (8.6±4.3 weeks) and
Non-Hispanic (8.2±4.6 weeks) women (p=0.45).

Almost half of women (45.0%) reported the presence of medical conditions
with diabetes being the most prevalent (20.1%). One third of the study
population (32.1%) had a history of adverse pregnancy outcomes, such as
miscarriage (32.1%), stillbirth (27.6%), terminated birth (7.5%), and ectopic
pregnancy (1.8%) Regarding tobacco use, most of women (87.0%) were not
current smokers or quit before pregnancy recognition, while only 13.0% of
participants reported smoking during some point of pregnancy.

Binge drinking (i.e., at least one episode of consuming ≥4 drinks per occasion)
during a month around the last menstrual period was reported by 23.1% of
women. Over half of women (53.4%) reported using prescription medications
during pregnancy, and 29.1% of women who used medications did not discuss
their safety in pregnancy with a health care provider.

Among 200 women who were asked questions about illicit drug use, 55 (27.5%)
reported lifetime use of at least one type of drugs and 11 (5.5%) women
reported use during the month prior to LMP or during the current pregnancy.
Among 352 who answered a question about pregnancy planning, 181 women
(51.4%) reported unplanned pregnancy.
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Vitamin Use Patterns
The vitamin use patterns were summarized in Table 4.2. In this population,
21.4% of women were identified as pre-conceptional vitamin users, 71.9% of
women began to take vitamin after they realized they were pregnant, and 6.7%
of women did not use any vitamins during pregnancy. Of note, there were
three women who began to take vitamin regularly in pre-conceptional period
but stopped taking after pregnancy recognition. All of the three women
reported a family history of birth defects (two women with a family history of
Down syndrome and the other woman with a family history of cleft lip/palate),
but reasons for this behavior change were not captured by this study. Among
vitamin users after pregnancy recognition, only one woman used a single
vitamin (folic acid), while the rest reported multivitamin use. This woman was
included into the study Group 2 for analysis. Among all vitamin users, 58.4% of
women used OTC multivitamins and 30.9% of women reported using
prescription multivitamins. The two most frequently identified brands of
prenatal vitamin were Walmart® and Walgreen® prenatal vitamins. Both of
these brands contain 800 microgram of folic acid. Other brands identified by
participants included “One a day Prenatals”, “Natalcare Plus”, and “Flinestone
vitamins”. On average, vitamins were taken 6 days (s.d=1.9) per week during
the week before the interview. Among women who took vitamin after
pregnancy recognition, the average initiation time was 9 weeks after the LMP.

Maternal Characteristics of Vitamin Use
The distributions of maternal characteristics among the three study groups
were summarized in Table 4.3. Only 17.3% of Hispanics took vitamin in
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pre-conceptional period, while most of them began to take vitamins only after
pregnancy recognition. There was a significant difference in the distribution of
education level among the three study groups. A decreasing trend of the
proportion of women with a college degree or higher education was identified:
50% of women with a college degree or higher education were identified
among pre-conceptional vitamin users, followed by vitamin users after
pregnancy recognition (47.5%) and vitamin non-users (2.5%). Interestingly,
the largest proportion of women with some college or vocational school
education was identified among vitamin users after pregnancy recognition
(66.3%), followed by pre-conceptional vitamin users (23.6%). Association
between the three study groups with respect to vitamin use and health
insurance was significant. The proportion of women who had Medicaid or other
public insurance among pre-conceptional vitamin users (44.9%) was closed to
the proportion in vitamin users after pregnancy recognition (49.0%). In sum,
there were significant associations among the three study groups with respect
to ethnicity, education level, health insurance, language speaking, and
pregnancy planning. Maternal age, race, marital status, primigravida,
nulliparous, place of birth, history of adverse pregnancy outcomes, presence
of medical conditions, a family history of birth defects or adverse pregnancy
outcomes, use of prescription medications, smoking status, periconceptional
drinking, periconceptional drug use, were not significantly associated with
vitamin use in this sample.
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Ordinal Logistic Regression
Results of ordinal multivariate logistic regression with cumulative odds ratios
(ORs) and 95% confidence intervals (95% CI) for each predictor were
summarized in Table 4.4. Cumulative ORs represent increasing odds of being
early vitamin users. The results of multivariate analysis showed that maternal
age, race, history of adverse pregnancy outcomes, country of birth, and use
prescription medications were not significant associated with vitamin use.
Moreover, ethnicity, education level, health insurance, and language speaking
became not significant after adjusting for other variables in the model. The only
significant predictor associated with vitamin use was pregnancy planning,
suggesting that the odds of being vitamin users at an earlier stage in
pregnancy were 1.76 times higher for women who had pregnancy planning
than those women who did not have a pregnancy planning.

Interactions between predictors were examined using the ordinal logistic
regression model and results were summarized in Table 4.5. Of note, there
were no women who identified themselves as Non-Hispanics and spoke
Spanish at the same time. Therefore, the interaction between ethnicity and
language speaking could not be calculated. The only significant interaction
was identified between education level and insurance status (p<0.05),
meaning that the effect of education on vitamin use varied by the level of
health insurance status. Thus, the association between education and vitamin
use was examined after stratification by insurance status. Results are
presented in Table 4.5 (women without health insurance), Table 4.6 (women
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with employer-based or self-purchased insurance), and Table 4.7 (women with
Medicaid or other public insurance).

Results of the stratified analysis demonstrate that there were no associations
between maternal education and vitamin use among women without health
insurance and women who had private or self-purchased health insurance.
However, among women with public health insurance, having a college degree
or higher was associated with greater odds of early vitamin use (OR=14.45;
95% CI: 1.78-117.66) compared to women with a high school education or
less.

Due to the limited sample size in each category of health insurance status, the
present analysis explored the interaction between education and health
insurance by categorizing health insurance into a dichotomous variable (any
type of insurance vs. none). Results were presented in Table 4.8 and Table 4.9,
respectively. Among women without insurance, education level was not a
significant predictor. However, among women with any type of insurance, the
odds of earlier vitamin use were greater among women with a college degree
or higher than women with a high school education or less (OR=5.90, 95%
CI:1.89-18.44).

Polychotomous Logistic Regression
The test for the proportional odds assumption resulted in a p=0.15. The null
hypothesis for the proportional odds assumption is that the assumption is met.
Given that p=0.15 is greater that a usually used cut-off point of p=0.1, the H0 is
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not rejected and once can conclude that the proportional odds assumption is
met. However, given that the p-value was close so close to the cut-off point,
polychotomous logistic regression was also conducted in additional to the
ordinal logistic regression.

All the significant covariates identified in univariate analysis at p<0.2 were
considered as potential predictors of vitamin use and were included in a
polychotomous logistic regression. As shown in Table 4.10, in the first logit of
the unadjusted polychotomous logistic regression (pre-conceptional vitamin
users vs. vitamin users after pregnancy recognition), significant predictors
were ethnicity, education, health insurance, pregnancy plan, language
speaking, and use of prescription medications during pregnancy. Specifically,
women who were pre-conceptional vitamin users were less likely to be
Hispanics (OR=0.33, 95% CI=0.19-0.57), speak Spanish (OR=0.43, 95%
CI=0.27-0.71), more likely to have a college degree or higher education
(OR=4.94, 95% CI=2.44-10.00), have employer-based or self-purchased
insurance (OR=3.90, 95% CI=1.97-7.75), and use ≥2 prescription medications
(OR=2.33, 95% CI=1.14-4.78) compared to women to initiated vitamin use
later in pregnancy. Maternal age, race, and history of adverse outcomes were
not significant in this analysis (p>0.05). In the second logit (non-users vs.
vitamin users after pregnancy recognition), race was the only significant
predictor. Specifically, non-users were more likely to be in the “other” racial
groups (OR=3.35, 95% CI=1.13-9.92) compared to vitamin users after
pregnancy recognition after adjusting for other risk factors.

42

Results of multivariate polychotomous logistic regression were present in
Table 4.11. After adjusting for ethnicity, race, education level, language
speaking, history of adverse pregnancy outcomes, place of birth, and use of
prescription medications during pregnancy, pregnancy planning was the only
significant predictor of using vitamins before pregnancy recognition as
compared to vitamin user after pregnancy recognition (OR=2.29, 95%
CI=1.29-4.09). Race was no longer significant in multivariate analysis for
comparison of non-users vs. users after pregnancy recognition. However, a
history of adverse pregnancy outcomes became a significant predictor:
non-users are more likely to have a history of adverse pregnancy outcomes
comparing to vitamin users after pregnancy recognition (OR=3.04, 95%
CI=1.16-7.98).

For interaction terms, Table 4.5 summarized the results and showed that there
were no significant interaction effects between ethnicity and race, ethnicity and
place of birth, race and language speaking, ethnicity and place of birth, place
of birth and language speaking, education and health insurance status,
education and pregnancy plan.
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CHAPTER IV: DISCUSSION
Summary
This study found that most pregnant women (71.9%) in the sample began to
take vitamins regularly after pregnancy recognition. For women who started to
use vitamins after pregnancy recognition, the mean gestational age of initiating
vitamin use was 9 weeks. Women on average took vitamins 6 times per week.
However, only 21.4% of study participants began to take vitamins before
pregnancy, thus had vitamin exposure in early gestation even before
pregnancy recognition. Most women reported using OTC vitamins (54.2%),
with two most popular brands being Walgreen® and Walmart® prenatal
vitamins, both containing 800mg of folic acid.

Hispanics were less likely to use vitamin early in pregnancy than
non-Hispanics;

however,

ethnic

difference

in

vitamin

use

became

non-significant after adjusting for other maternal characteristics. Unplanned
pregnancy is a big public health issue: half of participants, similar to national
estimates,94 in this study identified their pregnancies as unintended. Earlier
vitamin use in pregnancy was significantly associated with pregnancy planning
independent of other maternal characteristics. In addition, education level and
health insurance status revealed a significant interaction with respect to
vitamin use. Among women with public health insurance, the odds of early
vitamin use were greater among women with a college degree or higher
education than women with a high school education or less than high school.
In addition, almost one third (32.1%) of women in this study had a history of
adverse pregnancy outcomes and 45.0% of women had at least one medical
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condition. In multivariate analysis, vitamin non-users were more likely to have
experience of adverse pregnancy outcomes in prior pregnancies compared to
women who used vitamin after pregnancy recognition. This observation
requires investigation in future studies.

Prevalence of Vitamin Use as Compared to Other Studies
In this study, 92.5% of women reported regularly using vitamin anytime during
pregnancy. This prevalence rate is higher comparing to a cross-sectional study
using data from the Behavior Risk Factor Surveillance System (BRFSS), in
which 78% of women from 14 U.S. states and territories reported using
multivitamins in pregnancy.19 For vitamin use among Hispanics, the present
study identified that 76.2% of Hispanics were vitamin users anytime during
pregnancy, while this prevalence in the BRFSS study was 66.4%. Although the
estimation used a national sample, the BRFSS database did not contain
information on the duration of multivitamin use, doses, contents, or frequency
of use.

In additional to BRFSS, vitamin use during pregnancy was also investigated
using data from the National Maternal and Infant Health Survey (NMIHS). This
national survey defined vitamin use as vitamin/mineral supplement use at least
3 days a week. This definition was somewhat comparable to the present study
(vitamin use at least 4 times per week). There were two cross-sectional studies
which conducted analyses based on the NMIHS data. One of these studies
was limited to mothers of live-born infants and reported that 82.5% of women
used vitamin anytime during pregnancy,37 while the prevalence was 74.2%
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when the sample included women with miscarriages or women who terminated
their pregnanciesl.36 However, both of the prevalence estimates included
mineral supplement use. Therefore, women who reported using mineral
supplements only could be also included in these prevalence estimates. These
studies have not reported the prevalence of vitamin use among Hispanics
though, which comprised the majority of the sample in the present study.

Prescription claim databases were also used to estimate the prevalence of
vitamin use during pregnancy. A population-based study analyzed data from
the Kaiser Permanete Medical Care Program (KPMCP) in North California and
reported that 69.0% of women used vitamin during pregnancy. As compared to
the results of the present study, prevalence in the KPMCP was lower.35 The
difference might be due to the different gestational age at the interview time.
The KPMCP study recruited women at an earlier stage of pregnancy: the
mean gestational age at study entry was less than 5 weeks, while the mean
gestational age at current analysis was 30.7 weeks. The Pregnancy, Infection,
and Nutrition (PIN) Study in North Carolina recruited women from four prenatal
care clinics and reported that the prevalence of vitamin use anytime in
pregnancy was 84%.25 However, neither KPMCP study nor PIN study reported
vitamin use among Hispanics. Information on the duration of vitamin use and
frequency was not reported in these two studies.

Regarding vitamin use after pregnancy recognition, 71.9% of women in this
present analysis began to take vitamin after pregnancy recognition, which is
higher comparing to two previous prospective cohort studies in the U.S
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(44.8-48.9%).25,

35

One of these prospective cohort studies, however,

interviewed women who were at 24-29 weeks of pregnancy, and it potentially
excluded women at third trimester. Thus, the estimation of vitamin use might
not include women at higher risk of adverse birth outcomes. For the other
prospective cohort study, nearly half of women (49.4%) refused to participate
in the study. Furthermore, among all the participants, there were 23.2% of
women who did not complete an interview. Therefore, the result of vitamin use
after pregnancy recognition might suffer from a selection bias.

With respect to vitamin use in early pregnancy/pre-conceptional period, only
21.4% of women reported using vitamin in this present study. Similar to this
result, there were several Pregnancy Risk Assessment Monitoring System
(PRAMS) reports which investigate the vitamin regular use (≥4 times per week)
in pre-conceptional period. Centers for Disease Control and Prevention (CDC)
introduced PRAMS in 1987, and PRAMS is an ongoing surveillance system in
order to monitor maternal behaviors that occur before, during, and after
pregnancy.39 Several reports analyzed PRAMS data covered from 2000 to
2003 and reported that the prevalence of pre-conceptional vitamin regular user
ranged from 25.0 to 45.2% based on 19 states in the U.S.18, 39 Another PRAMS
report limited the sample to women in Oklahoma and found the prevalence fell
between this range (26.5%) from 2000 to 2003.81 Unfortunately, the
prevalence remained relatively unchanged. The latest PRAMS report
summarized data for 2003-2004 from 26 states and demonstrated that 35.1%
of women on average reported using vitamin in pre-conceptional period.47
Similar to the result of PRAMS, a state report using data from the Missouri
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Pregnancy Related Assessment and Monitoring System (MoPRA) found that
the prevalence of pre-conceptional daily vitamin use was 29.7%.86 These
results are comparable to our findings.

However, the results from PRAMS and MoPRA analyses might be have limited
generalizability since they only include women with live-born infants. Therefore,
the prevalence of pre-conceptional vitamin users might be overestimated,
given to a possibility that the sample did not include women who had a
miscarriage or stillbirth and did not use prenatal vitamins during the
pre-conceptional period. In addition, all the identified PRAMS reports and the
MoPRA

study

did

not

investigate

pre-conceptional

vitamin

use

by

race/ethnicity.

The prevalence of pre-conceptional vitamin use in this present analysis, to
some extent, might reflect the prevalence of periconceptional vitamin use. The
definition of periconceptional period varies across the studies and might refer
to one month before and one month after the LMP or might include as many as
three months before and after LMP. Women who reported using vitamin before
pregnancy are more likely to continue using vitamin after they were pregnant.
A cross-sectional study, which used data from the NMIHS, reported that the
prevalence of periconceptional vitamin use (≥3 times per week during three
months before and three months after pregnancy recognition) was 21%.36
Similarly, a Kaiser Permanete Medical Care Program (KPMCP) prospective
cohort study reported 23.8% prevalence.35 Therefore, the prevalence of
periconceptional vitamin use and pre-conceptional vitamin use were similar.
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The difference in maternal characteristics might explain variability in the
prevalence of periconceptional vitamin use. The PIN study reported that the
prevalence of periconceptional vitamin use (before and during pregnancy) was
30.0%.25 The higher prevalence rate of pre-conceptional vitamin use in PIN
study can be explained by the fact that this study included women who only
spoke English and that most of women (64.5%) in this study were
Non-Hispanic whites. Moreover, women who planned the pregnancy might be
more likely to use vitamin in periconceptional period. The NBDPS study
demonstrated that the prevalence of periconceptional vitamin use among
women who planned their pregnancy was 64.3%.79

There is also a difference in the prevalence of periconceptional vitamin use
among different racial groups. For Hispanics, data obtained from the National
Birth Defects Prevention Study (NBDPS) showed that the prevalence of
periconceptional intake of folic acid-containing supplements is only 30%
among Hispanics, which is the lowest compared to other racial groups
(Non-Hispanic White: 66%; Non-Hispanic Black: 39%).43 For other races, a
secondary analysis using data from the Slone Epidemiology Center Birth
Defects Study (SECBDS) showed that 55.0% of Non-Hispanic White women
were periconceptional vitamin users (used vitamins ≥ 4 times per week during
lunar months -1 to 1), while this prevalence was only 25.6% among African
American women.42
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There are many potential reasons for lower prevalence of vitamin use among
Hispanic women compared to Non-Hispanic Whites. One possible explanation
might be the lower awareness about benefits of folic acid in prevention of birth
defects and other adverse perinatal outcomes among Hispanic women. A
household survey conducted in predominantly Hispanics neighborhoods of
inner-city Hartford, Connecticut demonstrated that 78% of Hispanics (both
women and men) are not aware of NTDs, including spina bifida.95 Another
survey among Hispanic women of childbearing age conducted in Michigan and
showed that nearly half of study participants (45%) did not know about the time
window to prevent birth defects and 59% did not take daily multivitamins
before pregnancy recognition.96

With respect to the type of vitamins, more than half of women (54.2%) used
OTC vitamins during pregnancy, and 28.7% of women reported using
prescription vitamins. This result was quite different from a previous
prospective cohort study, which recruited pregnant women from rural outreach
clinics in the U.S. The result showed that 92.0% of pregnant women used
prescription

prenatal

multivitamins

and

10.9%

of

them

used

OTC

multivitamins.84 This discrepancy might be due to the different sampling
method. Glover’s study recruited all the women from obstetric patients who
were seen by private physicians, while a majority of study participants in our
study came from the university-affiliated community clinics providing free
prenatal care. The difference in the health insurance coverage could account
for the discrepancy between the two studies. In Glover’s study, all of the
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participants had heath insurance (e.g. Medicaid, private insurance), while
almost half of women (48.8%) in our study did not have any health insurance.

The average time of pregnancy recognition is 9.0 gestational weeks. The time
interval between the LMP and the pregnancy recognition is a curial period for
organogenesis. During the month of fertilization, cells along the dorsal surface
of the embryo develops into a groove and then a hollow tube.29 If this process
is not completed, a neural tube defect develops. A number of prior studies
suggested

that

periconceptional

use

of multivitamin supplementation

containing folic acid (from 3 months before and through 3 months after
conception) can significantly lower the risks of NTDs.2, 9-16 It has been strongly
recommended that all women of childbearing age should consume 400 μg of
folic acid daily given that 50% of pregnancies are unplanned.22 Regular
multivitamin use (≥4 times per week) provides the recommended amount of
folic acid.39 Nevertheless, in the present study, the result showed that most
women initiated vitamin regular use at 9 weeks after LMP, which is after the
closure of neural tube (six weeks after the last menstrual period). In our study,
there were only 21.4% of women who initiated vitamin use before pregnancy
recognition.

Predictors of Vitamin Use as Compared to Other Studies
Race/Ethnicity
The sample in the present analysis included a large proportion of Hispanics
women, but ethnic difference in vitamin use was non-significant after adjusting
for other maternal characteristics. The review of published literature showed
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that findings among different studies with respect to race/ethnicity are
inconsistent. A cross-sectional analysis of the BRFSS data did not
demonstrate that ethnicity was a significant predictor for vitamin use among
pregnant women.19 The analysis conducted in the MoPRA study also yielded
non-significant results after adjusting for other predictors.86 However, other
studies reported race/ethnicity to be a significant predictor. A study from the
Slone

Epidemiology

Center

Birth

Defects

Study

suggested

that

periconceptional vitamin users (-1 to +1 month around LMP) were more likely
to be non-Hispanic Whites.42 Another cross-sectional analysis, using data from
the NMIHS, found that vitamin non-users were more likely to be African
American and Asians. However, the NMIHS study mentioned above did not
assess the effect of Hispanic ethnicity on vitamin use.37

In terms of predominant language, Spanish was not a significant predictor of
vitamin use in the present study. This result contradicted the findings from a
cross-sectional study which used data from the National Birth Defects
Prevention Program (NBDPP). In that study, women who did not use vitamins
in periconceptional period (3 months before conception and one month after
conception) tended to speak Spanish. However, the difference in the
proportion of women who spoke Spanish may cause this difference. There
were only less than 5% of Spanish-speaking women (n=80) in the NBDPP
study, and the odds ratio was quite wide (OR=2.0-7.2), while our population
included 60% Hispanics. In addition, the present study explored the
relationship between place of birth and vitamin use. A population-based
case-control study, using data from California birth cohort, found that women
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who were Mexico descents had an increased risk of having a NTD-affected
pregnancy.46 However, this study did not specify the place of birth for the
participants. In this present analysis, this demographic characteristic was not a
significant predictor of vitamin use in pregnancy.

Maternal Education
Education was not a significant predictor of vitamin use during pregnancy or in
pre-conceptional period after adjusting for other maternal characteristics. The
result might due to the small sample of women with a college degree of higher
in our samples. However, our results are consistent with several
cross-sectional studies in the U.S. A cross-sectional analysis, using the 2004
data from the BRFSS, found that education was not a significant predictor of
vitamin use during pregnancy.19 Another report using the MoPRA data also
confirmed that education level was not significantly associated with
pre-conceptional vitamin use (one month before pregnancy recognition) after
adjusting other variables in the analysis.86

However, other studies found an association between vitamin use and higher
education level. For vitamin use anytime in pregnancy, a national survey
initiated by the Medical Birth Registry in Brazil and a cross-sectional analysis
using data from Norwegian Mothers and Child Cohort Study (MoBa) found that
vitamin users during pregnancy tended to have a college/university degree.74,
77

For periconceptional vitamin use, a cross-sectional analysis using data from

the Slone Epidemiology Center Birth Defects Study and the 2001 New South
Wales Child Health Survey in Australia found that periconceptional vitamin
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user (-1 to +1 month around LMP vs. -2 to +3 month around pregnancy
recognition) were those women with higher education level or more years of
education.42, 97 In addition, a PRAMS data and a cross-sectional analysis using
data from NMIHS found that women with at least 12 years of education were
significantly more likely to be pre-conceptional vitamin users (≥4 times per
week during the month before pregnancy) than women with less than high
school education (<12 years of education).39

The present analysis observed a significant interaction between health
insurance and education level in respect to vitamin use during early pregnancy.
Among women with public insurance, patients with a college degree or higher
education were more likely to be vitamin earlier users than women with only
high school or less than high school education. Among women who had
private insurance or did not have insurance, the present study did observe any
significant association between education and vitamin earlier use in pregnancy.
We did not find other studies which examined this interaction. Nevertheless, a
PRAMS report used data from 19 states and found that pre-conceptional
vitamin users (≥4 times per week during the month before pregnancy) were
more likely to have a private health insurance and have more than 12 years of
education, but it did not examine the interaction regarding pre-conceptional
vitamin use.39

Health Insurance
Even though there was a significant interaction between health insurance and
maternal education, health insurance status by itself was not a significant
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predictor of pre-conceptional vitamin use in the present analysis.

Prior

reports for this association are inconsistent. A cross-sectional analysis, using
data from MoPRA, examined the insurance status of pregnant women, but this
predictor was not significant.86 This result did not concur with the results of two
PRAMS reports, which used data during 2000-2003 in Oklahoma and
2003-2004 in 26 states, respectively. One of these reports found that the
highest prevalence of pre-conceptional vitamin users were women with private
health insurance. The other study further adjusted all other demographic
characteristics and found that pre-conceptional vitamin users were more likely
to be women with private health insurance than women who were recipients of
Medicaid.47, 81 It is worthy mentioning that the MoPRA study only asked women
whether they had insurance or not, but it did not specify the type of insurance,
which might cause the different result. The difference in findings between the
PRAMS reports and current study might be due to various maternal
characteristics of the study population between PRAM and the SMART study.
There were no other studies from Europe or Australia that investigated the
vitamin use in earlier pregnancy and health insurance status because of the
different national health care system.

Marital Status
With respect to marital status, this present analysis did not observe any
significant difference among the three study groups. A survey of postpartum
women in Toronto Hospital also did not detect a significant association.
However, a number of analyses presented a contrast to this result, suggesting
that married women or women living with a partner were more likely to be
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vitamin earlier users during pregnancy,19,

42, 78, 82, 85, 86

even though the

maternal characteristics varied by different studies. It is noteworthy that the
present analysis included a small number of women who were separated or
divorced. This might cause a non-significant result.

Maternal Age
Maternal age, measured as a continuous variable, was non-significant in the
present study. A cross-sectional study, recruiting women in the antenatal
clinics and birth center in Australia, also measured maternal age as a
continuous variable, but did not find it to be significant.75 However, a
prospective cohort study obtained data from the Pregnancy Exposure and
Preeclampsia Prevention Study in the U.S. and found that maternal age as a
continuous variable was a significant predictor of periconceptional vitamin use
(-3 to +3 months around LMP) from a chi square test. However, this study did
not calculate the odds ratio and did not adjust other maternal characteristics.

Even though the present analysis categorized this predictor into three age
groups, the present analysis still did not detect a significant result. Another
study in Canada surveyed postpartum women in Toronto Hospital and
categorized maternal age as three groups (<16-25, 26-30, 31-35),80 also
suggesting a non-significant result and being consistent to an analysis using
data from the BRFSS in 2004.19 On the contrary, there were also some studies
pointing out that older age group was associated with vitamin earlier use in
pregnancy.37, 39, 43, 47, 73, 81, 86 A potential reason for the different result between
these studies and the present study is due to the various maternal
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characteristics in different countries and areas. Also, the different way to
categorize maternal age may account for the different result. A cross-sectional
study in the U.S. conducted at MoPRA categorized women into two age
groups (<20 years, ≥20 years) and detected a significant result with respect to
pre-conceptional vitamin use.

Pregnancy Planning
Pregnancy planning identified by the present analysis was the only significant
predictor that associated with earlier vitamin use. This finding confirmed the
result from a cross-sectional study in the U.S. conducted at MoPRA. This
study suggested that planning of pregnancy was significantly associated with
pre-conceptional prenatal multivitamin intake (OR=2.04, 95% CI=1.45-2.94)
when the study adjusted other maternal characteristics.86 In addition, a study
obtained data from PRAMS during 2003-2004 reported that the highest
prevalence of pre-conceptional vitamin users were among women with
pregnancy intention. However, the PRAMS did not report the strength of
association.47 For other studies in the U.S., analyses using data from BRFSS,
NMIHS, and PRAMS did not involve pregnancy planning as a potential
predictor of vitamin use.19, 37, 39, 81

Although there are differences in maternal characteristics between various
populations in different countries, several studies from other countries also
detected a significant association between earlier vitamin use and pregnancy
planning. A cross-sectional study from Australia used data from a
population-based survey (the 2001 New South Wales Child Health Survey)
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and reported that women with an unplanned pregnancy (OR=0.15, 95%
CI=0.08-0.26) were significantly less likely to take periconceptional folic acid
supplementation (≥1 months before and 3 months after pregnancy
recognition).43 A survey conducted at the Department of Obstetrics and
Gynecology and in the Pregnancy Care Centre in Hungary also confirmed this
result: planning of pregnancy (OR=4.22, 95% CI=2.61-6.84) was significantly
associated

with

periconceptional

vitamin

intake

(before

and

during

pregnancy).83 Of note, in the survey, most participants (83.7%) had a
pregnancy planning, which is higher than the present analysis. Also, the
authors did not specifically defined periconceptional period. A cross-sectional
analysis from Canada defined periconceptional period (≥ 4 weeks prior to
conception until 8 weeks after conception) and surveyed a group of
postpartum women in Toronto Hospital. The result also supported that
unplanned pregnancy (OR=1.5, 95% CI=1.4-1.6) was significantly associated
with a lack of folic acid use in periconceptional period.80

Interestingly, pregnancy planning was not statistically associated with vitamin
use after pregnancy recognition in the present study. This result may support
the result of a cross-sectional study in Portugal. The study recruited mothers of
live-born infants from two primary hospitals in the North of Portugal, but it did
not observe a significant association between pregnancy planning and
multivitamin use in pregnancy (OR= 0.96, 95% CI=0.89-1.03). Admittedly,
there were other studies that also investigated the predictors of vitamin use in
pre-conceptional or periconceptional period,74,
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75, 77, 82, 85

but none of these

studies measured pregnancy planning for women or did not involve this
predictor for multivariate analysis.

History of Adverse Perinatal Outcomes
In this study, vitamin non-users were more likely to have a history of adverse
pregnancy outcomes comparing to vitamin users after pregnancy recognition
(OR=3.04, 95% CI=1.16-7.98). This result contradicted to a cross-sectional
study using data from the National Birth Defects Prevention Study (NBDPS). In
this analysis, women who did not take vitamins in periconceptional period (3
months before conception and 1 month after conception) tended to have no
previous miscarriage (OR=0.7 95% CI=0.5-0.9).43 However, non-users in the
present analysis were those who did not use vitamin anytime during pregnancy,
while this NBDPS report limited vitamin non-users to women who did not use
vitamin in periconceptional period. Moreover, the present analysis not only
investigated miscarriage but also other previous adverse pregnancy outcomes,
such as ectopic pregnancy, stillbirth, and elective pregnancy termination.
Difference in maternal characteristics might also account for the discrepancy.
All the women recruited from the NBDPS were mothers with live-born infants
without major malformations. There were other studies which also investigated
the association between vitamin use during pregnancy and previous adverse
pregnancy outcomes. One report obtained data from the Birth Registry in
Brazil examined the relationship between vitamin use during pregnancy and
previous experience of miscarriages as well as stillbirths.77 However, the result
was insignificant. Also, a study surveyed women in the antenatal clinics and
birth centre in Australia, but the association between periconceptional vitamin
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use (before and during pregnancy) and a history of adverse pregnancy
outcomes was not signfiicant.75

It is still unclear how previous adverse pregnancy outcomes associated with
vitamin use in pregnancy. The most likely explanation is that those non-vitamin
users did not use vitamin in the prior pregnancy either. However, the SMART
study did not investigate the reasons of not taking vitamins. Therefore, neither
of the two possibilities could be confirmed in this study.

Other Predictors
Other predictors associated with reproductive health included a family history
of birth defects, presence of chronic conditions, parity, and gravidity.
Unfortunately, none of them was significant in the present analysis. A
prospective cohort study, analyzing data from the Pregnancy Exposure and
Preeclampsia Prevention Study, also did not detect a significant relationship
between a family history of preeclampsia or hypertension and periconceptional
vitamin use (-3 to 3 months around LMP).24 For the presence of chronic
disease, although the SMART was inclusive of possible maternal medical
conditions, the present analysis still did not detect a significant association. A
prospective cohort study examined the presence of hypertension and
periconceptional vitamin use, but the result was also not significant. A PRAM
report examined data from 19 reporting areas during 2000 suggested that the
association

between

the

presence

of

gestational

diabetes

and

pre-conceptional vitamin use was not significant.39 For parity, there were
controversies about the relationship between parity and vitamin earlier use in
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pregnancy. One study in the U.S. used data from the National Birth Defects
Prevention Study found that women who did not take vitamin in
periconceptional period (-3 months to 1 month around conception) tended to
be nulliparous.43 Another study in Australia, analyzing data from the Victoria
Survey of Recent Mothers 2000 and the 2001 NSW Child Health Survey,
found a different result: periconceptional vitamin non-users (-2 to 3 months
around pregnancy recognition) were multiparous.97 The difference in maternal
characteristics between two countries might create this discrepancy.

Smoking during pregnancy was not a significant predictor. There were several
studies in the U.S. found that women who were not current smokers were
tended to be vitamin users in pregnancy,42, 43, 74, 86 but none of these studies
specified the time point when women stopped smoking. For alcohol and
recreational drug exposure in periconceptional period, the present analysis did
not observe any significant relationship with vitamin earlier use in pregnancy. A
study, using data from the National Birth Defects Prevention Study, also
examined yielded a similar result.43 Of note, this study focused on any alcohol
and recreational drug exposure from the three months before conception
through the time of delivery, while the present study limited drink exposure to
binge drink (≥4 drinks on one occasion) and recreational drug in
periconceptional period (the month around the last menstrual period).

Limitations
The first limitation of this study was that we relied on the self-reported
information from women. There is a possibility of outcome misclassification,
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because women might have had difficulty remembering their behaviors
regarding vitamin use before the interview or early in pregnancy. Recall bias
might cause missing values for some maternal characteristics and information
of vitamin use patterns. For instance, some women did not identify their family
history of birth defects or adverse pregnancy outcomes. However, comparing
to maternal characteristic, the present study had more missing values for
vitamin use patterns. Some women failed to identify the type or brand of
prenatal vitamins. There were also some women who could not specify the
date when they began to take vitamins. Similarly, due to the sensitive nature of
some questions (e.g. marital status, recreational drug use, periconceptional
binge drink), there is a possibility that women felt reluctant to report or might
not report their maternal behaviors accurately. In addition, potential interview
bias might also occur and impact on the validity of self-report information.

A second limitation of this study was that it did not capture the maternal
characteristics and vitamin use patterns for all the participants due to the
nature of the SMART study. The late introduction of some questions also
caused missing values for the present analysis. For instance, more than half of
participants did not have information on recreational drug use. Also, the
SMART study did not investigate pregnancy planning for the first 42 women.
The incomplete information of maternal characteristics might cause loss of
valid sample size for the analysis, thus reducing the power to detect significant
predictors. Furthermore, the SMART study did not capture all the relevant
maternal characteristics for vitamin use during pregnancy. For example, this
study did not ask women about their house income, while this demographic
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characteristic is a potential predictor of using vitamins during pregnancy. Given
to the large proportion of women without any health insurance and recipients
of Medicaid, it is likely that the study population included a large number of
women at low socioeconomic status. For vitamin use patterns, the SMART
study did not follow up vitamin use after the baseline interview. Therefore, this
analysis could not estimate the duration of vitamin use during the entire
process of pregnancy. In addition, the SMART study did not ask participants
about the reason of vitamin use or non-use.

The inclusion criteria of the SMART study affected the estimation of vitamin
use among all the pregnant women for the present analysis. The SMART
study ascertained eligible women with known pregnancy status, but it did not
include women with miscarriages that occur prior to this study. It is important to
explore their vitamin use during pregnancy, for most of these women might be
vitamin non-users.

In terms of generazability, the present study might limit the findings to the
women in New Mexico. The ethnic distribution was quite different from that in
the BRFSS and the PRAMS, for there were a large proportion of Hispanics
women in the present analysis. Additionally, the SMART study might not be
fully representative of all pregnant women in New Mexico, for it only captured
women who did attend UNM-affiliated prenatal care clinics.
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Strengths
The first strength of this study is that the validity of data from the SMART study
is high. There is a high degree of intended cooperation, given to the fact that
this study had a high participation rate (81.5%). For non-participation, the
SMART study also asked them to specify the reasons. All the interviewers in
the SMART study have previous experience of conducting interviews, and all
of them received a standardized training before the study. Thus, we have
reduced the interviews bias at the minimum level. Moreover, we realized that
there were a large number of Spanish-speaking women in New Mexico. Hence,
all the interviewers are bi-lingual and fluent in English in order to eliminate the
language barrier of communication.

The second strength of this study is that it provides comprehensive information
of vitamin use pattern. Firstly, we estimated the prevalence of vitamin use on a
regular basis, which is meaningful. Prior CDC report demonstrates that
multivitamin use at least four times per week can provide the recommended
amount of folic acid.39 Secondly, we categorized vitamin use in different time of
pregnancy and created three mutually exclusive vitamin user groups. Based
on this classification, we compared the different in maternal characteristics
among three groups. In addition, the study showed the type and the most
popular brands among vitamin users. Thirdly, for vitamin users after pregnancy
recognition, we attempted to estimate the time gap between the last menstrual
period and the initiate time of vitamin use. Knowing this time gap could help us
determine whether women missed the appropriate time for vitamin intake.
Lastly, although this study did not capture women who had a miscarriage

64

before enrollment, the present analysis included women who had pregnancy
ended in a stillbirth (no live birth; gestational age<20 weeks).

Thirdly, this is the first study which adopted an ordinal logistic regression
model and polychotomous logistic regression model for the analysis. With the
ordinal logistic regression model, we assumed that there was a natural
ordering across three vitamin user groups, and we were able to identify the
significant predictor associated with earlier vitamin use. The use of
polychotomous logistic regression enables this study to compare the
difference in maternal characteristics between pre-conceptional vitamin users
and vitamin users after pregnancy recognition. Additionally, the present
analysis is the first one which attempted to examine interactions between two
predictors.

The fourth strength of this study is that the population in SMART study has an
ethnically and socially-diverse sample. The present study is the first one which
investigated vitamin use in pre-conceptional period and after pregnancy
recognition using a sample primarily with Hispanic women.

Future Directions & Recommendations
For vitamin use among pregnant women, future studies should clearly define
“pre-conceptional period”, “periconceptional period”, and “anytime during
pregnancy”. The difference in these definitions can cause various results,
including both prevalence and predictors. Also, future studies need to select
the study population carefully. Only including mothers of live-born child might
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overestimate the prevalence of vitamin use in pregnancy. It is highly possible
that the prevalence could be lower if the sample also included women with a
miscarriage. In addition, to ascertain vitamin use, it is meaningful to define a
vitamin user as someone who takes multivitamins at least 4 times per week.
This meets the recommended amount of folic acid to prevent NTDs, according
to the CDC. Moreover, it is helpful to identify the type and brands of vitamins.
Therefore, researchers can determine the components and estimate the
amount of folic acid in each product. To ensure the compliance of vitamin
intake during pregnancy, future studies need to follow up and estimate the
duration of vitamin use. Last but not least, it is helpful to estimate the initiate
time for vitamin use, especially for women who started vitamin use after
pregnancy recognition. Women with late pregnancy recognition might miss the
right time to initiate vitamin use for preventing NTDs.

With regard to the questionnaire design and interviews, future study may need
to introduce Spanish or other foreign languages if the population includes
minorities or foreign immigrants. Also, considering that some participants
might fail to identify the type or brand of vitamins, researchers should provide a
sample or bottles of vitamin products. Interviewers could also ask participants
to show the vitamin products that they are using. To ascertain some sensitive
maternal behaviors (e.g. alcohol use, recreational drug use), future studies can
introduce biomarkers to certify the validity of self-report information. Lastly, the
reasons of not taking vitamins need to be further studied. Previous experience
of adverse pregnancy outcomes could mislead women into believing that
vitamin use in pregnancy might account for adverse pregnancy outcomes.
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Future studies need to assess the perception of vitamin use in pregnancy.
Public health campaign might incorporate appropriate education program in
order to change attitudes towards an earlier vitamin use during pregnancy.

Although the association between some maternal characteristics (e.g.
education, maternal age, BMI, health insurance, marital status) and vitamin
use were not significantly in the present study, it does not mean that these
factors do not account for the prevalence of vitamin use in early pregnancy.
The findings of the present study should be interpreted with caution. Future
studies need to explore these findings by recruiting a larger sample size.

There is a great need to develop prevention strategies to educate pregnant
women about benefits of prenatal vitamin use. Our study indicated that ethnic
minorities may particularly benefit from such education efforts. To begin with,
improving access to prenatal care for all pregnant women will facilitate greater
utilization of prenatal vitamins. For women who have financial or other barriers
to obtain vitamins, publicly funded clinics with free access to prenatal care
should be widely available. Health insurance companies can add multivitamin
into their prescription plans and formulary. Also, healthcare providers should
play a pivotal role in education of women at reproductive age. Specifically, they
should provide counseling to pregnant women and women who plan a
pregnancy in order to improve the patient’s knowledge of preventing NTDs and
to inform them about the benefits of taking vitamins. A March of Dimes survey
suggested that 89% of women would be more likely to take folic acid if advised
by health care providers.98 However, this survey also found that only 30% of
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women who were aware of folic acid cite health care providers as the source of
information about the benefits of folic acid use in pregnancy.98 Therefore, there
is a great need to incorporate healthcare providers as a part of the birth
defects prevention programs. A physician-based intervention, conducted at
Arkansas, suggested that a brief counseling from physicians can potentially
reduce the risk of folate-preventable birth defects among their patients by as
much as 11%.99 Besides physicians, pharmacists may also contribute to the
promotion of folic acid use among women of reproductive age by encouraging
them to take multivitamins. Moreover, the mass media, including printed media,
audio and visual media, Internet, can also serve to increase the awareness of
vitamin use at reproductive age. Lastly, additional research is needed to
ascertain the reasons of using or not using vitamins among pregnant women
or women who might become pregnant. Health behavior models, such as
Health Belief Model, Theory of Planned Behavior, may help to better
understand the patient’s decision making process with respect to vitamin use
during pregnancy and earlier initiation of prenatal care.

In sum, this study highlights the importance of promoting vitamin use in early
pregnancy among pregnant women in New Mexico, given to the finding that
only less than one third of women used vitamins during the pre-conceptional
period. The findings of this study can also provide an implication that public
health strategies to ensure early use of vitamin during pregnancy should
include the promotion of pregnancy planning.
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Author &
Date
Dott M
2010
U.S.

Study Design
Case-control
study

*Data from National
Birth Defects
Prevention study
1997-2002

Table 2.1. Prevalence of Multivitamin Use in Pregnancy
Population
Assessment of Vitamin
Prevalence
Comments
Use
N=4,094 mothers of Periconceptional period: Periconceptional nonPotential selection bias
live born infants
-1 month to +1 month
exists when this study
multivitamin users:
born during
did not capture mothers
around conception
41% (992/2437) of
1997-2002
whose current pregnancy
women without
ended in a miscarriage,
During pregnancy: not
pregnancy intent;
studied
64.3% (1059/1648) of stillbirth, or an infant with
Multivitamin: multivitamin women with pregnancy
a major birth defect,
containing folic
potentially resulting in an
intent
acid/prenatal
underestimate of the
impact of pregnancy
multivitamin
intention on maternal
Frequency: not studied
behaviors. Also, this
study may have recall
OTC & Rx: not studied
bias.
Single vitamin: not
studied

81

Author &
Date
Burris HH
2009
U.S.

Study Design

Population

Assessment of Vitamin
Use
Cross-sectional Control:
random Periconceptional period:
study
sample
of
-1 to +1 around LMP
Massachusetts
births
During pregnancy: not
studied
Case: Mothers of
malformed infants
Multivitamin: at least 2
*Data source: the
water-soluble vitamins+2
Slone Epidemiology
fat-soluble vitamins
Center Birth Defects
Study

Frequency: ≥4
times/week
OTC & Rx: not mention
Single vitamin: not
mention
Prenatal vitamin: not
mention

82

Prevalence
Periconceptional
multivitamin users:
55.0% of white women
vs. 25.6% of black
women

Comments

Author &
Date
Sullivan K
2009
U.S

Study Design

Population

Cross-sectional
study

N= 788 pregnant
women who were
ascertained from
20, 263 women
who aged from 18
to 44 years by 14
states and U.S
territories

*Data from
Behavioral Risk
Factor Surveillance
System(BRFSS)

Assessment of Vitamin
Use
Periconceptional period:
Not studied
During pregnancy:
studied but not defined
Multivitamin: not defined
Frequency: not studied
OTC & Rx: not studied
Single vitamin: not
studied
Prenatal multivitamin:
not studied

83

Prevalence

Comments

Multivitamin users in
pregnancy: 78% of
pregnant women
reported multivitamin
use.

Women were asked
whether they currently
used multivitamin or not.
Information about the
duration of multivitamin
use, dose, contents, and
frequency was not
collected

Author &
Date
Avalos LA
2009
U.S.

Study Design

Population

Prospective
Cohort study

N=1,061 women
who was at their
first pregnancy,
speaking English,
have pregnancy
intentness and
whose gestational
age at the
pregnancy test was
less than or equal
to 10 complete
weeks

*Data: women
members in the
Kaiser Permanente
Medical Care
Program (KPMCP)

Assessment of Vitamin
Use
Periconceptional period:
began prior pregnancy
and in pregnancy (not
specifically defined)
During pregnancy: since
become pregnant or
LMP
Multivitamin:
multivitamin/prenatal
vitamin
Frequency: any use (not
specifically defined)
OTC & Rx: not studied
Single vitamin: studied
but not presented

84

Prevalence
Periconceptional
multivitamin users:
23.8% (252/1061)

Comments

Multivitamin status is an
important modifier in the
relationship between
pregnancy drinking and
During pregnancy:
miscarriage: the risk of
68.8% (730/1061)
miscarriage was greatest
for women who drank
Prenatal multivitamin
alcohol and reported no
users who begin to use
multivitamin
multivitamin during
supplementation
pregnancy: 44.8%
(475/1061)
Multivitamin non-users:
31.2% (331/1061)

Author &
Date
Venkata
P.S
2008
U.S.

Study Design

Assessment of Vitamin
Prevalence
Use
Cross-sectional N=1,789 mothers in Pre-conceptional period:
Pre-conceptional
study
Missouri who
one month before
multivitamin users:
delivered the
29.7% (every day a
became pregnant
previous 2-6
week), 5.0% (4-6 times
months
During pregnancy: not
per week), 10% (1-3
studied
times per week)
*Data: Missouri
Pregnancy Related
Assessment and
Monitoring System
(MoPRA)

Population

Multivitamin:
multivitamin/prenatal
vitamin
Frequency: 1-3/4-6/7
times per week
OTC & Rx: not studied
Single vitamin: studied
but not presented

85

Comments

Author &
Date
Catov JM
2007
U.S.

Study Design
Prospective
Cohort study

*Data from the
Pregnancy
Exposure and
Preeclampsia
Prevention Study

Population

Assessment of Vitamin
Use
N=1,823 women
Periconceptional period:
who enrolled at less 6 months which included
than 16 weeks and
prior to conception, at
followed through the
the time of conception
postpartum visit
immediately after
conception (not
specifically defined)
During pregnancy: not
studied
Multivitamin:
multivitamin/prenatal
vitamin
Frequency: at least
once/week
OTC & Rx: not studied
Single vitamin: not
studied

86

Prevalence

Comments

Periconceptional
multivitamin users:
47%

The study relied on
self-reported
multivitamin use. Also,
This study lack of
information on the brand
or dose of supplement
periconceptional vitamin
supplementation is
associated with preterm
birth (<34 weeks) has
been reported by others

Author &
Date
D’Angelo D
et al
2007
U.S.

Study Design

Population

Cross-sectional
study

Women from 26
PRAMS reporting
areas

*Data from
Pregnancy Risk
Assessment
Monitoring
System(PRAMS)
During 2003-2004

Assessment of Vitamin
Use
Preconceptional period:
before pregnancy (1
month before, 3 months,
12 months before
pregnancy)
Periconceptional period
&
During pregnancy: not
studied
Multivitamin:
multivitamin/prenatal
vitamin
Frequency: at least 4
times/week
OTC & Rx: not studied
Single vitamin/prenatal
vitamin: not studied

87

Prevalence
Pre-conceptional
multivitamin users:
35.1% (26.7% in
Arkansas – 43.6%
Rhode Island)

Comments

Author &
Date
CDC (not
listed)
2007
U.S.

Study Design

Population

Cross-sectional
study

Women from
PRAMS in
Oklahoma

*Data from
Pregnancy Risk
Assessment
Monitoring
System(PRAMS)
During 2000-2003

Assessment of Vitamin
Use
Preconceptional period:
during the month before
pregnancy
Periconceptional period
&
During pregnancy: not
studied
Multivitamin:
multivitamin/prenatal
vitamin
Frequency: at least 4
times/week
OTC & Rx: not studied
Single vitamin/prenatal
vitamin: not studied

88

Prevalence
Pre-conceptional
multivitamin users:
26.5%

Comments

Author &
Date
Suellentrop
et al
2006
U.S.

Study Design
Cross-sectional
study
*Data from
Pregnancy Risk
Assessment
Monitoring
System(PRAMS)
During 2000-2003

Population
Women from 19
PRAMS reporting
areas

Assessment of Vitamin
Use
Pre-conceptional period:
during the month before
pregnancy
Periconceptional period
&
During pregnancy: not
studied
Multivitamin: not defined
Frequency: at least 4
times/week
OTC & Rx: not studied
Single vitamin/prenatal
vitamin: not studied

89

Prevalence

Comments

Pre-conceptional
multivitamin users:
23.0% in Arkansas to
45.2% in Maine

Sectional bias may exist
because only women
with live infants were
included

Author &
Date
Carmichael
2006
U.S.

Study Design

Population

Cross-sectional
analysis

N=2518 women
with estimated
delivery dates from
1997-2000

*Data from the
National Birth
Defects Prevention
Study

Assessment of Vitamin
& Folic acid Use
Pre-conceptional period:
not studied
Periconceptional period:
3 month before
conception/one month
after conception

Predictors

Comments

Periconceptional
vitamin non-users:
53%

Participants were
mothers of live-born
infants without major
malformation

Earlier pregnancy:
35%
Later pregnancy: 8%

Earlier pregnancy: the
second and third month
after conception
Later pregnancy: during
the fourth month or later
during pregnancy
Multivitamin:
multivitamin/prenatal
vitamin: folic acid
supplementation
Frequency: not defined
OTC & Rx/prenatal
vitamin: not studied

90

Author &
Date
Glover et al
2003
U.S

Study Design

Population

Prospective
cohort study

N=578 participants
from four rural
outreach clinics
between August
1999 and
November 2001

Assessment of Vitamin
Use
Periconceptional period:
not studied
During pregnancy: since
LMP

Prevalence

Comments

Multivitamin users in
pregnancy: 92%
(prescribed prenatal
vitamin) vs. 10.9%
(OTC multivitamins)

Multivitamin: not defined
Frequency: studied but
not presented
OTC & Rx: separately
reported (Rx
multivitamin was defined
as a prenatal vitamin)
Single vitamin: vitamin C
was reported
Prenatal multivitamin:
not studied

91

Vitamin C users in
pregnancy: 2.4% (14)

Information about the
duration of multivitamin
use, dose, contents, and
frequency was not
mentioned

Author &
Date
Vahratian
2004
U.S.

Study Design

Population

Assessment of Vitamin
Use
Cross-sectional Women who were Periconceptional period:
analysis
at 24-29 weeks of
Before and during
pregnancy from 4
pregnancy (not
prenatal care clinics
specifically defined)
in central North
*Data: Pregnancy,
Carolina
During pregnancy: any
Infection, and
time during pregnancy
Nutrition (PIN) study
up until the time of
interview or recruitment
(24-29 gestational
weeks)
Multivitamin: not defined
Frequency: studied but
not presented
OTC & Rx/prenatal
vitamin: not studied
Single vitamin: folate,
vitamin A, vitamin C was
studied but not reported

92

Prevalence

Comments

Periconceptional
multivitamin users:
30%
Prenatal multivitamin
users: 54%

Frequency of
multivitamin use, type of
multivitamin was not
studied in this analysis

Author &
Study Design
Date
Williams LM Cross-sectional
2000
study
U.S.
*Data from
Pregnancy Risk
Assessment
Monitoring System
(PRAMS) 2000

Population
N=32,479 women
who were identified
from 19 states and
U.S territories

Assessment of Vitamin
Use
Pre-conceptional period:
during the month before
pregnancy
Periconceptional period
&
During pregnancy: not
studied
Multivitamin: not defined
Frequency: at least 4
times/week
OTC & Rx/prenatal
vitamin: not studied
Single vitamin: not
studied

93

Prevalence

Comments

Pre-conceptional
multivitamin users:
25.0%--40.7%
Because data are
self-reported 2--8
months after delivery,
responses might be
subject to recall bias,
particularly for behaviors
and experiences that
occurred before the
pregnancy

Author &
Date
Wu T
1998
U.S

Study Design

Population

Assessment of Vitamin
Use
Cross-sectional N=12,465 women
Periconceptional period:
study
were identified from -3 to +3 months around
livebirth, fetal
pregnancy recognition
death, infant death
certifications from
During pregnancy: 3
the National
months after pregnancy
*Data from the
Maternal and Infant
recognition
National Maternal
Health
Survey
and Infant Health
Multivitamin: not defined
Survey
Frequency: at least 3
times/week
OTC & Rx/prenatal
vitamin: not studied
Single vitamin: vitamin
A, vitamin C, folic acid
were studied but not
reported

94

Prevalence

Comments

Periconceptional
multivitamin/mineral
users: 21%

Multivitamin and mineral
supplements were
combined and could not
be separated for further
analysis

Multivitamin/mineral
users during
pregnancy: 53.8%

Author &
Date
Scholl TO
1997
U.S.

Study Design

Population

Prospective cohort
study

N=1,430 low
income, urban
women who
entered prenatal
care during the first
and second
trimesters and who
had singleton
pregnancies.

Assessment of
Vitamin Use
Periconceptional
period:
Not studied
During pregnancy:
after pregnancy
recognition
Multivitamin: prenatal
multivitamin/mineral
supplements
Frequency: not
studied
OTC & Rx: not studied
Single vitamin: not
studied

95

Prevalence

Comments

Multivitamin/supplements
users during pregnancy:
80.4%

Multivitamin and
mineral supplements
were combined, and
there was insufficient
information on the use
of multivitamin such
as type of
multivitamin,
frequency, or length
of ingestion

29.3% (418/1430) at the
first trimester vs. 730
51.0% (730/1430) during
the second trimester

Author &
Date
Milunsky
1989
U.S.

Study Design

Population

Cross-sectional
analysis

N=22,776 pregnant
women who had a
either maternal
serum
a-fetoprotein(MSAF
P) screen or an
amniocentesis
around 16 weeks of
gestation

Assessment of
Vitamin Use
Periconceptional
period: -3 to +3 months
around LMP

Periconceptional
multivitamin users:
31.9% (n=7261)

During pregnancy: 3
months after LMP

Multivitamin non-users:
12.9% (n=2927)

Multivitamin: not
defined
Frequency: studied but
not reported
OTC & Rx/prenatal
vitamin: not studied
Single vitamin: vitamin
A, vitamin C, vitamin E,
folic acid were studied
but not reported

96

Prevalence

Comments

Author &
Date
Yu SM
1996
U.S.

Study Design

Population

Cross-sectional
study

N=9,953 women
who delivered live
infants in the 1988
National Maternal
and Infant Health
Survey

Assessment of Vitamin
Use
Periconceptional period:
not studied
During pregnancy: after
pregnancy recognition
Multivitamin: not defined

*Data from the
National Maternal
and Infant Health
Survey

Frequency: ≥3
times/week
OTC & Rx/prenatal
vitamin: not studied
Single vitamin: vitamin A,
vitamin C, vitamin E, folic
acid were studied but not
reported

97

Prevalence

Comments

Multivitamin-mineral
supplement users:
82.5% (67% of Black
mothers vs. 84% of
White mothers)

Multivitamin and mineral
supplements were
combined,

Author &
Date
Tam LE
2004
Canada

Study Design

Population

Cross-sectional
analysis

N=383 postpartum
women in Toronto
Hospital and the
Mount Sinai
Hospital

Assessment of Vitamin
Use
Periconceptional period:
at least 4 weeks prior to
conception until 8 weeks
after conception
During pregnancy: not
studied
Multivitamin: not defined
Frequency: not studied
OTC & Rx/prenatal
vitamin: not studied
Single vitamin: not
studied

98

Prevalence
Periconceptional
multivitamin users:
28%

Comments

Author &
Date
Alwan NA
2010
United
Kingdom

Study Design

Population

prospective
cohort study

N=1,274 women
who aged at 18-45
years with low-risk
pregnancies were
prospectively
recruited at 8-12
weeks of gestation
from the Leeds
Teaching Hospital
maternity unit
between 2003 and
2006

Assessment of Vitamin
Use
Periconceptional period:
not studied
During pregnancy: from
the first trimester to the
third trimester

Prevalence

Comments

Multivitamin-mineral
supplement users
during pregnancy: 23.3
% (293/1274) in the
first trimester, 14.1%
(177/1274) in the
second trimester, and
18.6% (79/425)*.

Data on using
multivitamin-mineral
preparation was mixed
and could not be
separated.

Multivitamin: not defined
Frequency: not studied
OTC & Rx/prenatal
vitamin: not studied
Single vitamin: vitamin A,
B6, B12, C, D, E were
studied but not
prevalence rate was
reported

99

* Only 425 women had
information on
supplement intake in
the third trimester.

Author &
Date
KÄLLÉN
2003
Sweden

Study Design

Population

Prospective
Cohort study

N=3675 women
who were at their
first visit to the
antenatal care unit
and return
questionnaire
around gestational
week 28.

Assessment of Vitamin
Use
Periconceptional period:
before pregnancy and
the first two months after
pregnancy (not
specifically defined)
During early pregnancy:
first two months
Multivitamin: not defined
Frequency: not studied
OTC & Rx/prenatal
vitamin: not studied
Single vitamin: not
studied
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Prevalence

Comments

Periconceptional
multivitamin users:
19.3% (2525/3675)

The study explored the
relationship between
vitamin use, smoking,
and nausea and vomiting
of pregnancy, but it does
not focus on the
predictors of the use of
multivitamin/vitamin

Multivitamin user
during early
pregnancy: 7.8%
(286/3675) of women
used vitamin only in
early pregnancy.

Author &
Date
Catov JM
2009
Denmark

Study Design

Population

Prospective
Cohort study

N=26,601
women who were
recruited in Danish
National Birth
Cohort and
completed revised
recruitment form

*Data from Danish
National Birth
Cohort

Assessment of Vitamin
Use
Periconceptional period:
-4 wks to +8 wks around
LMP
During pregnancy: not
studied
Multivitamin: not defined
Frequency: at least
once/week
OTC & Rx/prenatal
vitamin: not studied
Single vitamin: vitamin A,
B1, B12, B6, B12, C, D,
E, and folic acid were
studied but prevalence
rates were not reported

101

Prevalence

Comments

Periconceptional
multivitamin users:
65% (18,551/26601)

Regular periconceptional
multivitamin use is
associated with a
reduced risk of
preeclampsia among
normal-weight women

Author &
Date
Paulik E
2009
Hungary

Study Design

Population

Cross-sectional
study

N=349 voluntary
pregnant women
who were at the
Department of
Obstetrics and
Gynecology and in
the Pregnancy
Care Center

*Data from a
self-administrated
questionnaire
(response
rate=69.8%)

Assessment of Vitamin
Use
Periconceptional period:
not studied
During pregnancy: not
defined
Preconception period:
Not defined
Multivitamin: not defined
Frequency: not defined
OTC & Rx: not studied
Single vitamin: folic acid

102

Prevalence
Preconception
multivitamin regular
users: 43.8%
(153/349)
Preconception folic
acid regular users:
31.5% (110/349)
Multivitamin regular
users in pregnancy:
48.4% (141/349)
Folic acid regular users
in pregnancy: 40.4%
(141/349)

Comments

Author &
Date
Haugen M
2008
Norway

Study Design

Population

Assessment of Vitamin
Use
Cross-sectional N=40,817 Pregnant Periconceptional period:
study
women in Norway
not studied
who were 17-18
*Data from
weeks of gestation
During pregnancy: first
Norwegian Mothers
and participates in
4-5 months
and Child Cohort
study
between
Study(MoBa)
February 2002 and Multivitamin: not defined
February 2005
Frequency: never/<1/1-7
times per week
OTC & Rx/prenatal
vitamin: not studied
Single vitamin: vitamin
A, B1, B12, B6, B12, C,
D, E, and folic acid were
studied but prevalence
rates were not reported
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Prevalence
Multivitamin users in
the first 4-5 months of
pregnancy: 16.3%

Comments

Author &
Date
Vollest SE
2000
Norway

Study Design
Prospective
cohort study

Population

Assessment of Vitamin
Use
N=1,140 Norwegian Periconceptional period:
women who aged
before or during the first
18-45 years
2-3 months of their last
recent pregnancies

Prevalence
Periconceptional
multivitamin users
(daily or almost daily):
19.8%

During pregnancy: not
defined

Periconceptional
Vitamin B users: 3.6%

Multivitamin: not defined

Periconceptional folic
acid users: 2.4%

Frequency: daily or
almost daily/less
frequent than daily/
almost daily/never
OTC & Rx/prenatal
vitamin: not studied
Single vitamin: vitamin B,
folic acid
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Comments

Author &
Date
Lunet N
2008
Portugal

Study Design

Population

Cross-sectional
analysis from a
case-control
study

N=836 mothers
who were
interviewed 24-72
hours after delivery
at two major public
hospitals in the
North of Portugal

Assessment of Vitamin
Use
Periconceptional period:
not studied,
During pregnancy:
without exactly refer to
exact trimester
Multivitamin: not defined
Frequency: not studied
OTC & Rx/prenatal
vitamin: not studied
Single vitamin: folic acid

105

Prevalence

Comments

Multivitamin uses in
pregnancy: 76.2%

Frequency of
multivitamin use and the
content of multivitamin
was not mentioned in
this study;

Folic acid users in
pregnancy: 55.4%

Author &
Date
Nilsen RM
2008
Norway

Study Design

Population

Cross-sectional
Analysis

N=226,724 women
who have been
recorded by
Medical Birth
Registry of Norway
from 1998 through
2004

*Data from Medical
birth registry of
Norway

Assessment of Vitamin
Use
Periconceptional period:
before and during
pregnancy (not
specifically defined)
During pregnancy: not
defined
Multivitamin:
multivitamin alone/folic
acid alone/both folic acid
and multivitamin
Frequency: not studied
OTC & Rx: not studied
Single vitamin/prenatal
vitamin: not studied
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Prevalence

Comments

Periconceptional
multivitamin and/or
folic acid users: 15.9%

The prevalence of using
each supplement type
can not be separated
from the data

Multivitamin and/or
folic acid users in
pregnancy: 27.3%

Author &
Date
Forster D
2009
Australia

Study Design

Population

Cross-section
al survey

N=588 women
were approached in
the antenatal clinic
and the birth centre
at around 36-38
weeks gestation

Assessment of
Vitamin Use
Periconceptional
period: before and
during pregnancy (not
specifically defined)
During pregnancy: not
defined
Multivitamin: folic acid
alone/folic acid with
multivitamin/folic acid
with other vitamin
Frequency: does/day
and length of time were
recorded
OTC & Rx/prenatal
vitamin: not studied
Single vitamin: folic
acid, vitamin B6
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Prevalence

Comments

Periconceptional
multivitamin users: 7.8%
(46/587)

A combination of folic
acid and multivitamin
intake in different time of
pregnancy was provided.

Multivitamin users not
before pregnancy but
during pregnancy:
26.9% (158/587)

Author &
Date
Maats FH
2002
Australia

Study Design

Population

Cross-section
al
study(Hospital
-based
sample)

N=211 women who
were 26 weeks
gestation or more

Assessment of
Vitamin Use
Periconceptional
period: during the three
months prior to
pregnancy
During pregnancy:
from the 1st trimester to
the 3rd trimester.
Multivitamin/: not
defined
Frequency: studied but
not reported
OTC & Rx/prenatal
vitamin: not studied
Single vitamin: folic
acid alone or folic acid
combined with
multivitamins
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Prevalence
Periconceptional
multivitamin users: 26
(12%)
Multivitamin users in
pregnancy: 33(16%) in
the first trimester,
37(18%) in the second
trimester, 39(18%) in the
third trimester,
respectively.

Comments

Author &
Date
Wehby G
2009
Brazil

Study Design

Population

Assessment of Vitamin
Use
Cross-sectional N=1,774 mothers of Periconceptional period:
analyses(Birth
liveborn infants
not studied
registry data)
without congenital
malformations
During pregnancy: not
between 1995 and
defined
2001 in Brazil
Multivitamin:
multivitamin/prenatal
vitamin
Frequency: any use
during pregnancy (not
specifically defined)
OTC & Rx: not studied
Single vitamin: not
studied
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Prevalence

Comments

Multivitamin users in
pregnancy: 14%

This study evaluate the
demand for multivitamins
both pooled and
stratified by African
ancestry based on
maternal report of the
ancestries of the infant

Author &
Date
Burris HH
2009
U.S.

Study Design
Cross-sectional
study
*Data source: the Slone
Epidemiology Center
Birth Defects Study

Table 2.2. Predictors of Multivitamin Use in Pregnancy
Population
Assessment of Vitamin
Predictors
& Folic acid Use
Control: random Periconceptional period: -1
Periconceptional
sample
of to +1 month around LMP
multivitamin users:
Massachusetts
white women,
births
During pregnancy: not
non-smokers, married,
Case: Mothers of
studied
older, wealthier (annual
malformed infants
household≥$45,000),
and better educated
Multivitamin: at least 2
(above high school
water-soluble vitamins+2
fat-soluble vitamins
education)
Frequency: ≥4 times/week
OTC & Rx: not mention
Single vitamin: not
mention
Prenatal multivitamin: not
mention
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Comments
**Periconceptional:
28 days prior to the
last menstrual period
to after 28 days after
the last menstrual
period

Author &
Date
Sullivan K
2009
U.S.

Study Design
Cross-sectional
study
*Data from Behavioral
Risk Factor Surveillance
System(BRFSS)

Population

Assessment of Vitamin
& Folic acid Use
Periconceptional period:
Not studied

N=20, 263 women
who aged from 18
to 44 years by 14
states and U.S
During pregnancy: studied
territories
but not defined
Multivitamin: not defined
Frequency: not studied
OTC & Rx/prenatal
vitamin: not studied
Single vitamin: not studied
Prenatal multivitamin: not
studied
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Predictors

Comments

Multivitamin users
during pregnancy:
Higher Income (annual
household≥$50,000)
Marital status (married
or previously married)

Based on 14 U.S
states, the
generalizability of the
results is limited.
Information about the
duration of
multivitamin use,
dose, contents, and
frequency was not
collected

Author &
Date
Venkata
P.S
2008
U.S.

Study Design

Assessment of Vitamin
Use
Cross-sectional N=1,789 mothers in Pre-conceptional period:
study
Missouri who
one month before
delivered the
became pregnant
previous 2-6
months
During pregnancy: not
studied
*Data: Missouri
Pregnancy Related
Assessment and
Monitoring System
(MoPRA)

Population

Multivitamin:
multivitamin/prenatal
vitamin
Frequency: 1-3/4-6/7
times per week
OTC & Rx: not studied
Single vitamin: studied
but not presented
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Predictors
Periconceptional
multivitamin regular
users (≥4 times/week):
Intended pregnancy,
high house income
(≥35,000), married,
non-smoker, more
educated (≥12 years),
older (≥20 years)

Comments

Author &
Date
D’Angelo D
et al
2007
U.S.

Study Design

Population

Cross-sectional
study

Women from 26
PRAMS reporting
areas

*Data from
Pregnancy Risk
Assessment
Monitoring
System(PRAMS)
During 2003-2004

Assessment of Vitamin
Predictors
Use
Preconceptional
Preconceptional period:
multivitamin users:
before pregnancy (1
older (≥35 years),
month before, 3 months,
white women, intended
12 months before
pregnancy, had private
pregnancy)
health insurance
Periconceptional period
&
During pregnancy: not
studied
Multivitamin: not defined
Frequency: at least 4
times/week
OTC & Rx: not studied
Single vitamin/prenatal
vitamin: not studied
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Comments

Author &
Date
CDC (not
listed)
2007
U.S.

Study Design

Population

Cross-sectional
study

Women from
PRAMS in
Oklahoma

*Data from
Pregnancy Risk
Assessment
Monitoring
System(PRAMS)
During 2000-2003

Assessment of Vitamin
Predictors
Use
Preconception
Preconceptional period:
during the month before Multivitamin non-users:
Younger (<20 & 20-24)
pregnancy
or, unmarried, < 12
Periconceptional period years of education, no
health insurance,
&
enrolled in Medicaid
During pregnancy: not
studied
Multivitamin:
multivitamin/prenatal
vitamin
Frequency: at least 4
times/week
OTC & Rx: not studied
Single vitamin/prenatal
vitamin: not studied
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Comments

Author &
Date
Carmichael
2006
U.S.

Study Design

Population

Cross-sectional
analysis

N=2518 women
with estimated
delivery dates from
1997-2000

*Data from the
National Birth
Defects Prevention
Study

Assessment of Vitamin
& Folic acid Use
Preconceptional period:
not studied
Periconceptional period:
3 months before
conception/one month
after conception
Earlier pregnancy: the
second and third month
after conception
Later pregnancy: during
the fourth month or later
during pregnancy
Multivitamin:
multivitamin/prenatal
vitamin: folic acid
supplementation
Frequency: not defined
OTC & Rx/prenatal
vitamin: not studied
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Predictors

Comments

Periconceptional
vitamin non-users:
race (nonwhite),
language speaking
(Spanish), education
(low education),
maternal age
(younger<25), parity
(nulliparous), smoke
(current smoker), a
history of miscarriage
(no history of
miscarriage)

Participants were
mothers of live-born
infants without major
malformation

Author &
Date
Williams LM
2000
U.S.

Study Design

Population

Cross-sectional
study

N=32,479 women
who were
identified from 19
states and U.S
territories

*Data from Pregnancy
Risk Assessment
Monitoring
System(PRAMS)

Assessment of Vitamin
& Folic acid Use
Preconceptional period:
during the month before
pregnancy
Periconceptional period &
During pregnancy: not
studied
Multivitamin:
multivitamin/prenatal
vitamin
Frequency: at least 4
times/week
OTC & Rx/prenatal
vitamin: not studied
Single vitamin: not studied
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Predictors

Comments

Preconceptional users:
Education (>12 years),
age (>35 years),
non-Medicaid
recipients

Because data are
self-reported 2--8
months after delivery,
responses might be
subject to recall bias,
particularly for
behaviors and
experiences that
occurred before the
pregnancy

Author &
Date
Catov JM
2007
U.S.

Study Design

Population

Prospective
cohort study

N=1,823 women
who enrolled at
less than 16
weeks and
followed through
the postpartum
visit

*Data from the
Pregnancy Exposure
and Preeclampsia
Prevention Study

Assessment of Vitamin
& Folic acid Use
Periconceptional period: 6
months which included
prior to conception, at the
time of conception
immediately after
conception (not
specifically defined)
During pregnancy: not
studied
Multivitamin:
multivitamin/prenatal
vitamin
Frequency: at least
once/week
OTC & Rx: not studied
Single vitamin: not studied
.
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Predictors

Comments

Periconceptional
multivitamin users:
higher level of
education, married, of
normal body mass
index (18.5-24.9), and
to have participated in
moderate or vigorous
physical activity in the
year before becoming
pregnancy

The study relied on
self-reported
multivitamin use.
Also, This study lack
of information on the
brand or dose of
supplement

Author &
Date
Yu S
1996
U.S.

Study Design

Population

Cross-sectional
study

N=9953 women who
delivered live infants
in the 1988 National
Maternal and Infant
Health Survey

*Data: National
Maternal and Infant
Health Survey

Assessment of Vitamin
& Folic acid Use
Periconceptional period:
not studied

Predictors

Multivitamin non-users
before pregnancy:
black, unmarred,
During pregnancy: after
age<30 or
pregnancy recognition
20<age<34, less than
or only have a high
Multivitamin: not defined
school education,
Multivitamin non-users
Frequency: ≥3 times/week
during pregnancy:
black/Asia, younger,
OTC & Rx/prenatal
low education,
vitamin: not studied
unmarried, smoking
status.
Single vitamin: vitamin A,
age, race (white),
vitamin C, vitamin E, folic
socioeconomics
acid were studied but not
married status
reported
(married), education
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Comments
The self-report
nature of the
mothers'
questionnaire data
poses certain
limitations to the
study

Author &
Date
Tam LE
2004
Canada

Study Design

Population

Cross-sectional
analysis

N=383 postpartum
women in Toronto
Hospital and the
Mount Sinai
Hospital

Assessment of Vitamin
& Folic acid Use
Periconceptional period:
at least 4 weeks prior to
conception until 8 weeks
after conception
During pregnancy: not
studied
Multivitamin: not defined
Frequency: not studied
OTC & Rx/prenatal
vitamin: not studied
Single vitamin: not studied

119

Predictors

Comments

folic acid non users in
pregnancy: unplanned
pregnancy; lack of
knowledge about folic
acid
Periconceptional folic
acid/multivitamin
users are more likely
to be Jewish decent,
parity (≥1)

marital status,
education, family
income were not
significant

Author &
Date
Paulik E
2009
Hungary

Study Design

Population

Cross-sectional
study

N=349 voluntary
pregnant women
who were at the
Department of
Obstetrics and
Gynecology and in
the Pregnancy
Care Center

*Data from a
self-administrated
questionnaire
(response
rate=69.8%)

Assessment of Vitamin
Predictors
Use
Periconceptional period: Pre-conceptional folic
not studied
acid users: age (older),
pregnancy planning
During pregnancy: not
defined
Folic acid users in
pregnancy: age (older),
Pre-conceptional period:
gestational age
Not defined
(younger)
Multivitamin: not defined
Frequency: not defined
OTC & Rx: not studied
Single vitamin: folic acid
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Comments
Multivitamin use in
pregnancy or
preconception was
correlated with folic acid
use

Author &
Date
Nilsen RM
2008
Norway

Study Design

Population

Medical birth
registry

N=226,724
women who have
been recorded by
Medical Birth
Registry of
Norway from
1998 through
2004

Assessment of Vitamin
& Folic acid Use
Periconceptional period:
before and during
pregnancy (not specifically
defined)
During pregnancy: not
defined
Multivitamin: multivitamin
alone/folic acid alone/both
folic acid and multivitamin
Frequency: not studied
OTC & Rx: not studied
Single vitamin/prenatal
vitamin: not studied
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Predictors

Comments

Periconceptional
multivitamin users:
order (≥25), married or
cohabiting,
primiparous,
non-smoker

The prevalence of
using each
supplement type can
not be separated from
the data

multivitamin users
during pregnancy have
the same predictors

Author &
Date
Vollest SE
2000
Norway.

Study Design

Population

Cross-sectional
study

N=1,140
Norwegian
women who aged
18-45 years

*Data: a national survey
initiated by the Medical
Birth Registry and the
National Council on
Nutrition and Physical
Activity

Assessment of Vitamin
& Folic acid Use
Periconceptional period:
before or during the first
2-3 months of their last
recent pregnancies
During pregnancy: not
defined
Multivitamin: not defined
Frequency: daily or almost
daily/less frequent than
daily/ almost daily/never
OTC & Rx/prenatal
vitamin: not studied
Single vitamin: vitamin B,
folic acid
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Predictors

Comments

Periconceptional
multivitamin users:
young (18-24), high
education
(university/college
degree), married

Household was not
significant(p=0.25) in
multiple logistic
regression result

Author &
Date
Forster D
2009
Australia

Study Design
Cross-sectional
survey

Population

Assessment of Vitamin
& Folic acid Use
N=588 women
Periconceptional period:
were approached
before and during
in the antenatal
pregnancy (not specifically
clinic and the birth
defined)
centre at around
36-38 weeks
During pregnancy: not
gestation
defined
Multivitamin: folic acid
alone/folic acid with
multivitamin/folic acid with
other vitamin
Frequency: does/day and
length of time were
recorded
OTC & Rx/prenatal
vitamin: not studied
Single vitamin: folic acid,
vitamin B6
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Predictors

Comments

Multivitamin non-users
during pregnancy:
unmarried/living with a
partner, low income
(annual house
income<$30,000),
Low education, parity
(≥1)

The author did not
undertook regression
analysis to explore
the predictor of the
use of multivitamin
during
periconceptional
period

Author &
Date
Waston
2006
Australia

Study Design

Population

Cross-sectional
survey

N=1240 women
who gave birth in
Victoria

*Data: the Victoria
Survey of Recent
Mothers 2000 and the
2001 NSW Child Health
Survey

Assessment of Vitamin
& Folic acid Use
Periconceptional period:
1-2 months before
pregnancy recognition+ 3
months after pregnancy
recogntiion
During pregnancy: after
pregnancy recognition
Multivitamin: folic acid
supplementation
Frequency: daily (7 times
per week)
OTC & Rx/prenatal
vitamin: not studied
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Predictors
Folic acid non-users in
periconceptional
period: age (younger),
education (lower
education), income
(less income),
language speaking
(Non-English
speaking), marital
status (unmarried),
parity (multiparous),
pregnancy planning
(unplanned), living
area (rural area)

Comments

Author &
Date
Haugen M
2008
Norway

Study Design
Cross-sectional
study
*Data from Norwegian
Mothers and Child
Cohort Study(MoBa)

Population

Assessment of Vitamin
& Folic acid Use
Periconceptional period:
not studied

N=40,817
Pregnant women
in Norway who
were 17-18 weeks During pregnancy: first 4-5
of gestation and
months
participates in
study between
Multivitamin: not defined
February 2002
and February
Frequency: never/<1/1-7
2005
times per week
OTC & Rx: not studied
Single vitamin: vitamin A,
B1, B12, B6, B12, C, D, E,
and folic acid were studied
but prevalence rates were
not reported
prenatal vitamin: not
studied
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Predictors

Comments

Multivitamin users in
pregnancy: age (≥25),
BMI(≤24.9), smoking
status during
pregnancy
(non-smokers), parity
(primiparous),
education (≥10 years
of education)

Multivitamin use was
combined with
mineral use and other
dietary supplements.
It could not be
separated from data

Author &
Date
Lunet N
2008
Portugal

Study Design

Population

Cross-sectional
analysis from a
case-control study

N=836 mothers
who were
interviewed 24-72
hours after
delivery at two
major public
hospitals in the
North of Portugal

Assessment of Vitamin
Use
Periconceptional period:
not studied,
During pregnancy: without
exactly refer to exact
trimester

Predictors

Comments

Folic acid
supplementation
non-users during
pregnancy: marital
status (single),
pregnancy planning
(unplanned);

Frequency of
multivitamin use and
the content of
multivitamin was not
mentioned in this
study;

Multivitamin: not defined
Frequency: not studied
OTC & Rx/prenatal
vitamin: not studied
Single vitamin: folic acid
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Multivitamin users:
education (less
educated)

Table 3.1. Sample size calculations for different effect sizes
Effect size
20%
30%
40%
50%
60%

N1
63
28
13
9
6

N2
189
84
39
27
18

Total N
225
112
52
36
24

Two-sided Z tests were used with 1:3 ratio at alpha level 0.05
N1: required sample size for pre-conception multivitamin regular users
N2: required sample size for multivitamin regular users during pregnancy
Total N: the total required sample size in both groups
Effect size: the difference in the proportion of multivitamin user between the study groups
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Power
0.80
0.82
0.81
0.83
0.82

Table 4.1 Characteristics of the Study Population (N=402)
Maternal
N (%)a
Characteristics
Hispanics
323 (80.4)
Race*
White Non‐Hispanic
49 (12.2)
White Hispanic
298 (74.3)
Black or African American
23 (5.7)
American Indian or Alaskan Native
27 (6.7)
Asian or Asian American or Pacific Islander
3 (0.8)
Some other group
1 (0.3)
Educational Level
Less than high school graduate
141 (35.1)
High school graduate or GED
132 (32.8)
Some college or vocational school
89 (22.1)
College degree
28 (7.0)
Master, doctorate or professional degree
12 (3.0)
Marital Status
Single, never married
95 (23.6)
Married, living with spouse
168 (41.8)
Not married, but living with partner
120 (29.9)
Separated
15 (3.7)
Divorced
4 (1.0)
Widowed
0
Health Insurance Status
No insurance
196 (48.8)
Employer‐based insurance
45 (11.2)
Self‐purchased insurance
4 (1.0)
Medicaid
110 (27.4)
Other public insuranceb
47 (11.7)
Language Speaking
Spanish speaking
244 (60.7)
English speaking
152 (37.8)
Other language speaking
6 (1.5)
Country of Birth: U.S.
163 (40.6)
Primigravida
89 (22.2)
Nulliparous
130 (32.5)
History of Adverse Pregnancy Outcomes
129 (32.1)
Miscarriage (<20 wk of gestation)
110 (27.6)
Stillborn child (≥ 20 wk of gestation)
17 (4.3)
Terminated birth
30 (7.5)
Ectopic pregnancy
7 (1.8)
Presence of Chronic Condition(s)
181 (45.0)
Diabetes
81 (20.1)
Depression
26 (6.5)
Asthma or Allergies
35 (8.8)
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Table 4.1 (Continued) Characteristics of the Study Population (N=402)
Maternal
N (%)a
Characteristics
A Family History of Birth Defect(s) or Adverse
76 (19.3)
Pregnancy Outcome
Down syndrome
12 (3.0)
Cleft lip or palate
4 (1.0)
Neural tube defect
5 (1.2)
Cystic fibrosis
0
Heart defect
6 (1.4)
Otherc
63 (15.7)
Obesity (BMI≥30)
104 (25.9)
Pregnancy Planning
Yes
171 (48.6)
No, not now
110 (31.3)
No, not at any time
71 (20.2)
Smoking Status
Non‐smoker
294 (73.3)
Past smoker, quit before pregnancy
55 (13.7)
recognition
Past smoker, quit after pregnancy recognition
41 (10.2)
Current smoker
11 (2.7)
Periconceptional Binge Drinker
93 (23.1)
Periconceptional Recreational Drug User
11 (5.5)
Use of Prescription Medications during
Pregnancy
None
187 (46.6)
1‐2 medications
165 (41.2)
More than 2 medications
49 (12.2)
Mean±s.d
Maternal Age (yrs)
27.6±6.1
Gestational Age at Enrollment (wks)
30.7±8.0
a

Sample size might vary due to missing values
Other public insurance: UNM/UNM Care (7.0%, 28/402), Indian Health Service (1.0%, 4/402),
First Choice (1.0%, 3/402)
c
Other birth defect or adverse perinatal outcome: miscarriage (9.7%, 39/402), stillbirth (1.7,
7/402)
b
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Table 4.2 Descriptive Statistics of Multivitamin Use Patterns (N=402)
Pattern of Use
N (%)
Three Study Groups
Group 1‐Pre‐conceptional vitamin users
86 (21.4)
Group 2‐Vitamin users after pregnancy
289 (71.9)
recognition*
Group 3‐Vitamin non‐users
27 (6.7)
Prescription vs. OTC Multivitamin
Prescription vitamins
116 (28.7)
OTC vitamins
219 (54.2)
Non‐specified
40 (6.7)
The Most Common Brands of Vitamin**
Wal‐Mart prenatal vitamin
87 (21.6)
Walgreen prenatal vitamin
50 (12.4)
Mean±s.d
Initiation of regular vitamin use (gestational
9.0±7.2 wks
weeks)***
Number of days of vitamin use per week
6.0±1.9 days
* There is only one woman who used single vitamin (folic acid) after pregnancy recognition,
and she was still included in the Group 2.
** The sample size is limited to group 1 and group 2
*** The sample size is limited to group 2
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Table 4.3 Characteristics of the Study Participants by Vitamin Use
Group 3
P
Maternal
Group 1
Group 2
a
a
a
(n=27)
value
Characteristics
(n=86)
(n=289)
%
%
%
Hispanics
17.3
76.2
6.5
<0.01
Maternal age (yrs)
0.16
≤21 yrs
13.8
75.0
11.3
21‐30 yrs
24.7
69.6
5.7
>30 yrs
21.1
73.4
5.5
Race*
0.20
Whites
21.0
72.9
6.1
Black or African American
17.4
78.3
4.4
Some other groups
21.0
72.9
6.1
Educational Level
<0.01
High school education or less
16.5
77.3
6.2
Some college or vocational school
23.6
66.3
10.1
College degree or higher
50.0
47.5
2.5
Marital Status
0.44
Single, never married
20.0
72.6
7.4
Married or with a partner
22.9
70.8
6.3
Separated/divorced/widowed
5.3
84.2
10.5
Health Insurance Status
<0.01
No insurance
17.7
76.0
6.1
Medicaid or other public insurance
44.9
49.0
6.1
Employer‐based or self‐purchased
18.5
73.9
7.6
Spanish‐Speaking
16.0
77.9
6.2
<0.01
Primigravida
23.6
70.8
5.6
0.79
Nulliparous
25.4
70.0
4.6
0.23
History of Adverse Pregnancy
25.4
65.9
8.7
0.15
Outcomes
Presence of Chronic Condition(s)
22.7
69.1
8.3
0.40
A family History of Birth Defect(s)
26.3
67.1
6.6
0.53
Country of Birth: U.S
27.0
66.3
6.8
0.07
Obesity (BMI≥30)
25.4
67.7
6.9
0.32
Planned Pregnancy
26.9
66.7
6.4
0.04
Smoking Status
0.40
Non‐smoker
20.8
72.1
7.1
Past, quit before pregnancy
30.9
61.8
7.3
recognition
Smoker in pregnancy
15.4
80.8
3.9
Periconceptional Binge Drinker
21.5
69.9
8.6
0.66
Periconceptional Recreational Drug
18.2
81.8
0
0.52
User
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Table 4.3 (Continued) Characteristics of Study Participants by Vitamin Use
Group 2
Group 3
P
Maternal
Group 1
a
a
a
(n=289)
(n=27)
value
Characteristics
(n=86)
%
%
%
Use of Prescription Medications
0.16
during Pregnancy*
None
17.1
74.9
8.0
1‐2 types of medications
23.0
71.5
5.5
More than 2 types of medications
32.7
61.2
6.1
Mean±s.d
Maternal Age (yrs)
28.5±5.5
27.4±6.2 26.3±6.7 0.18
Gestational Age at Enrollment 31.2±7.8
30.5±8.1 31.6±7.3 0.63
(wks)
a

Sample size might vary due to missing values
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Table 4.4 Predictors of Vitamin Use: Results of Multivariate Ordinal Logistic
Regression Analysis*
Maternal Characteristics
ORs
95% CL
P value
Hispanics
0.68
0.29‐1.61
0.38
Maternal age (yrs)
0.62
≤21 yrs
‐‐
‐‐
‐‐
21‐30 yrs
1.88
0.95‐3.71
0.07
>30 yrs
1.27
0.61‐2.65
0.53
Race
Whites
‐‐
‐‐
‐‐
Black or African American
0.77
0.28‐2.13
0.61
Some other groups
0.33
0.11‐1.04
0.06
Educational Level
High school education or less
‐‐
‐‐
‐‐
Some college or vocational school
1.06
0.56‐2.04
0.86
College degree or higher
2.47
0.91‐6.72
0.08
Health Insurance Status
No insurance
‐‐
‐‐
‐‐
Employer‐based or self‐purchased
1.42
0.46‐4.46
0.54
Medicaid or other public insurance
0.82
0.38‐1.78
0.61
Spanish‐speaking
0.69
0.22‐2.13
0.52
History of Adverse Pregnancy
0.87
0.52‐1.47
0.61
Outcomes
Country of Birth: U.S
0.76
0.24‐2.44
0.64
Planned Pregnancy
1.77
1.08‐2.89
0.02
Use of Prescription Medications
during Pregnancy
None
‐‐
‐‐
‐‐
1‐2 types of medications
1.52
0.89‐2.59
0.13
More than 2 types of medications
2.17
0.94‐4.99
0.07
* All Odds ratios are adjusted for all variables in the table
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Table 4.5 Interaction between Predictors in Ordinal Logistic Regression and
Polychotomous logistic Regression Model
Interaction
Ordinal Logistic
Polychotomous
Regression
Logistic Regression
P‐value
P‐value
Ethnicity*Race
0.20
0.91
Ethnicity*Place of Birth
0.13
0.48
Ethnicity*Language Speaking
N.A
N.A
Race*Language Speaking
0.29
0.89
Race*Place of Birth
0.44
0.68
Place of Birth*Language Speaking
0.17
0.69
Education*Health Insurance Status
0.01
0.96
Education*Pregnancy Plan
0.69
0.85
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Table 4.6 Predictors of Vitamin Use: Results of Multivariate Ordinal Logistic
Regression Analysis among Women without Health Insurance*
Maternal Characteristics
ORs
95% CL
P value
Educational Level
High school education or less
‐‐
‐‐
Some college or vocational school
2.11
0.70‐6.34
0.18
College degree or higher
0.24
0.03‐2.17
0.20
* Odds ratio was adjusted for ethnicity, maternal age, race, language speaking,
history of adverse pregnancy outcomes, country of birth, pregnancy planning, and
use of prescription medications were adjusted.

Table 4.7 Predictors of Vitamin Use: Results of Multivariate Ordinal Logistic
Regression Analysis among Women with Private Insurance *
Maternal Characteristics
ORs
95% CL
P value
Educational Level
High school education or less
‐‐
‐‐
Some college or vocational school
0.09
0.01‐1.32
0.08
College degree or higher
0.33
0.02‐6.73
0.47
* Odds ratio was adjusted for ethnicity, maternal age, race, language speaking,
history of adverse pregnancy outcomes, country of birth, pregnancy planning, and
use of prescription medications were adjusted.

Table 4.8 Predictors of Vitamin Use: Results of Multivariate Ordinal Logistic
Regression Analysis among Women with Public Insurance *
Maternal Characteristics
ORs
95% CL
P value
Educational Level
High school education or less
‐‐
‐‐
Some college or vocational school
1.04
0.39‐2.80
0.94
College degree or higher
14.45
1.78‐117.66
0.01
* Odds ratio was adjusted for ethnicity, maternal age, race, language speaking,
history of adverse pregnancy outcomes, country of birth, pregnancy planning, and
use of prescription medications were adjusted.
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Table 4.9 Predictors of Vitamin Use: Results of Multivariate Ordinal Logistic
Regression Analysis among Women without Insurance*
Maternal Characteristics
ORs
95% CL
P value
Educational Level
High school education or less
‐‐
‐‐
Some college or vocational school
2.11
0.70‐6.34
0.18
College degree or higher
0.24
0.03‐2.17
0.20
* Odds ratio was adjusted for ethnicity, maternal age, race, language speaking,
history of adverse pregnancy outcomes, country of birth, pregnancy planning, and
use of prescription medications were adjusted.

Table 4.10 Predictors of Vitamin Use: Results of Multivariate Ordinal Logistic
Regression Analysis among Women with Insurance*
Maternal Characteristics
ORs
95% CL
P value
Educational Level
High school education or less
‐‐
‐‐
Some college or vocational school
0.92
0.39‐2.17
0.85
College degree or higher
5.90
1.89‐18.44
<0.01
* Odds ratio was adjusted for ethnicity, maternal age, race, language speaking,
history of adverse pregnancy outcomes, country of birth, pregnancy planning, and
use of prescription medications were adjusted.
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Table 4.11 Predictors of Vitamin Use: Results of Univariate Polychotomous
Logistic Regression Analysis*
Maternal Characteristics
Group 1 vs. Group 2
Group 3 vs. Group 2
ORs
95% CL
ORs
95% CL
Hispanics
0.33
0.19‐0.57
0.61
0.23‐1.60
Maternal age (yrs)
≤21 yrs
1.00
‐‐
1.00
‐‐
21‐30 yrs
1.94
0.94‐3.99
0.54
0.21‐1.38
>30 yrs
1.57
0.72‐3.39
0.50
0.18‐1.40
Race
Whites
1.00
‐‐
1.00
‐‐
Black or African American
0.77
0.25‐2.35
0.67
0.09‐5.26
Some other groups
1.54
0.64‐3.69
3.35
1.13‐9.92
Educational Level
High school education or less
1.00
‐‐
1.00
‐‐
Some college or vocational
1.67
0.92‐3.02
1.89
0.80‐4.47
school
College degree or higher
4.94
2.44‐10.00
0.65
0.08‐5.18
Health Insurance Status
No insurance
1.00
‐‐
1.00
‐‐
Employer‐based or
3.90
1.97‐7.75
1.28
0.56‐2.96
self‐purchased
Medicaid or other public
1.06
0.62‐1.84
1.55
0.41‐5.91
insurance
Spanish‐speaking
0.43
0.27‐0.71
0.65
0.29‐1.45
History of Adverse Perinatal
0.67
0.41‐1.10
1.17
0.49‐2.79
Outcomes
Country of Birth: U.S
1.76
1.08‐2.82
1.15
0.52‐2.57
Planned Pregnancy
1.95
1.15‐3.30
1.13
0.48‐2.65
Use of Prescription medications
during pregnancy
None
1.00
‐‐
1.00
‐‐
1‐2 medications
1.41
0.83‐2.39
0.71
0.30‐1.69
More than 2 medications
2.33
1.14‐4.78
0.93
0.25‐3.43
* All Odds ratios are adjusted for all variables in the table
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Table 4.12 Predictors of Vitamin Use: Results of Polychotomous Multivariate
Logistic Regression Analysis*
Maternal Characteristics

Group 1 vs. Group 2
ORs
95% CL
0.62
0.24‐1.59

Hispanics
Maternal age (yrs)
≤21 yrs
1.00
‐‐
21‐30 yrs
1.57
0.68‐3.63
>30 yrs
0.95
0.38‐2.40
Race
Whites
1.00
‐‐
Black or African American
0.50
0.14‐1.81
Some other groups
0.64
0.16‐2.56
Educational Level
High school education or less
1.00
‐‐
Some college or vocational
1.34
0.63‐2.86
school
College degree or higher
2.73
0.92‐8.07
Health Insurance Status
No insurance
1.00
‐‐
Employer‐based or
1.88
0.52‐6.80
self‐purchased
Medicaid or other public
0.83
0.33‐2.09
insurance
Spanish‐speaking
0.37
0.09‐1.58
History of Adverse Prenatal
1.32
0.73‐2.40
Outcomes
Country of Birth: U.S
0.32
0.07‐1.47
Planned Pregnancy
2.29
1.29‐4.09
Use of Prescription Medications
during Pregnancy
None
1.00
‐‐
1‐2 types of medications
1.52
0.81‐2.84
More than 2 types of
2.00
0.80‐5.01
medications
* All Odds ratios are adjusted for all variables in the table
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Group 3 vs. Group 2
ORs
95% CL
0.87
0.13‐5.70
1.00
0.41
0.46

‐‐
0.13‐1.29
0.13‐1.56

1.00
0.45
3.90

‐‐
0.05‐4.09
0.71‐21.37

1.00
1.36

‐‐
0.46‐4.05

0.70

0.06‐7.81

1.00
2.38

‐‐
0.31‐18.47

1.03

0.26‐4.04

0.34
3.04

0.03‐3.46
1.16‐7.98

0.20
1.31

0.02‐1.91
0.52‐3.29

1.00
0.75
0.46

‐‐
0.28‐2.02
0.05‐4.19

APPENDICES

Question

APPENDIX A Data Dictionary for SMART Study
Variable name Categories

Value

GENERAL INFORMATION
Subject ID
Date of interview
Location of interview

Algorithm for
assigning Subject IDs

subjID
dateint
locat

Text
Date (mm/dd/yy)
UNMH Fetal
Monitoring Clinic
(FMC)

First two digits
–Locat1009036
5ion
Next two
digits- Year of
interview
Last four
digits- Serial
no.

Triage
General
Satellite Clinic-West
Mesa
Satellite Clinic- South
Broadway
Satellite Clinic C
Satellite Clinic D
Other
First two digits for
location:
UNMH Fetal
Monitoring Clinic
(FMC)
Triage
General
Satellite Clinic-West
Mesa
Satellite Clinic- South
Broadway
Satellite Clinic –North
Valley
Satellite Clinic D
Other
Next two digits for
year of interview:
2008

If location is “Other”,
please specify
Prenatal care provider’s
last name
Examiner’s last name

locatot

Last four digits for
serial no.:
Text

obgyn

Text

examln

Text
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1
2
3
4
5
6
7
8

10
20
30
41
42
43
44
50

08
0001-01
24

Question
Patient’s phone number

Variable name
patpn

Categories
Text

Value

DEMOGRAPHICS
How old are you?
What is your marital
status now?

Are you Hispanic,
Latino or of Spanish
descent?
How do you describe
yourself?

momage
mommarit

Continuous
Single, never married
Married, living with
spouse
Not married, but living
with partner
Separated from
spouse
Divorced
Widowed
Yes
No

mometh
race

White Non-Hispanic
White Hispanic
Black or African
American
American Indian or
Alaskan Native
Asian or Asian
American or Pacific
Islander
Some other group
Prefer not to report
Tribe
Pueblo

If race is American
race3
Indian or Alaskan
Native, then specify
If race is others, then
raceoth
specify
What is the highest
momedlev
level in school you have
completed?

What is your health
insurance status?

1
2
3
4
5
6
1
0
0
1
2
3
4
5
6
1
2

Text
Less than high school
graduate
High school graduate
or GED
Some college or
vocational school
College degree
Masters, doctorate or
professional degree
No insurance
Employer-based
insurance
Self-purchased
insurance
Medicaid
Other public

momins
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1
2
3
4
5
1
2
3
4
5

Question

Variable name

If you have other public
health insurance, then
specify

momins5

Does your insurance
cover prescription
drugs?
Were you born in the
Unites States?
How long have you
lived in the United
States?
What language do you
mostly use at home?

prescov

If some other language
is used mostly at home,
then specify
Do you currently smoke
cigarettes or use
tobacco?
If yes, how many
cigarettes do you
usually smoke in a day?
If no, have you smoked
>100 cigarettes in your
life?
If you have smoked
>100 cigarettes in your
life, when did you stop
smoking?
Have you ever drank
alcohol?

momlang3

How many drinks
typically can you hold
before you feel high?
How many drinks
typically can you hold
before passing out or
falling asleep?
What was the first day
of your last menstrual
period?
During a month or so
around your last
menstrual period before

HIGH

Continuous

HOLD

Continuous

lmenst

Date (mm/dd/yy)

drink4m

Continuous

usborn

Categories
insurances
Indian Health Service
VA
First Choice
UNM/UNM Care
Yes
No

Value
1
2
3
4
1
0

Yes
No
Continuous

1
0

English
Spanish
Some other language
Text

1
2
3

smkmom

Yes
No

1
0

smkpreg

Continuous

smkmp1

Yes
No

1
0

smkstop

Before I became
pregnant
After I realized that I
was pregnant
Yes
No

1
2

momyr
momlang

havdrnk
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1
0

Question
you got pregnant, how
many times did you
drink 4 or more drinks
on one occasion?
During the year before
you got pregnant, did
close friends or relatives
worry or complain about
your drinking habits?
During the year before
you got pregnant, did
you ever take a drink
first thing in the morning
to get yourself going?
During the year before
you got pregnant, did a
friend or family member
tell you about things you
said or did while you
were drinking that you
could not remember?
During the year before
you got pregnant, did
you feel you need to cut
down on your drinking?

Variable name

Categories

worry

Yes
No

1
0

eyem

Yes
No

1
0

amnesm

Yes
No

1
0

cutm

Yes
No

1
0

TWEAK SCORE

tweak1 (High)
tweak2 (Hold)
Algorithm for calculating TWEAK HIGH
TWEAK score
TOLERANCE:
2, when no. of
drinks >=3; 0 if
no. of drinks <3
WORRY:
Yes= 2 points;
No= 0 pts.
EYEM:
Yes= 1 pt., No=
0 pt
AMNESM:
Yes= 1 pt., No=
0 pt
CUT:
Yes= 1 pt., No=
0 pt
TWEAK HOLD
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Continuous

Value

Question

Variable name
TOLERANCE:
2, when no. of
drinks >=6; 0 if
no. of drinks <6
WORRY:
Yes= 2 points;
No= 0 pts.
EYEM:
Yes= 1 pt., No=
0 pt
AMNESM:
Yes= 1 pt., No=
0 pt
CUT:
Yes= 1 pt., No=
0 pt

Categories

Value

MEDICAL AND REPRODUCTIVE HEALTH
What was your
pre-pregnancy weight?
What was your
pre-pregnancy height?
Researcher Calculated
BMI
Do you have a medical
condition or problem
that requires ongoing,
periodic, or occasional
treatment?
If yes, specify

wtmpre

Continuous

htmpre

Continuous

BMI

Continuous

medcon

Yes
No

1
0

Hypertension (High BP)

medcon1

Yes
No

1
0

Depression

medcon2

Yes
No

1
0

Diabetes

medcon3

Yes
No

1
0

Anxiety

medcon4

Yes
No

1
0

Seizure Disorder

medcon5

Yes
No

1
0
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Question
Migraine headaches

Variable name
medcon6

Categories
Yes
No

Value
1
0

Thyroid disorder

medcon7

Yes
No

1
0

Rheumatoid Arthritis

medcon8

Yes
No

1
0

Asthma or Allergies

medcon9

Yes
No

1
0

Heart Disease

medcon10

Yes
No

1
0

Cancer

medcon11

Yes
No

1
0

Hepatitis

medcon12

Yes
No

1
0

Other (s)

medcon13

Yes
No

1
0

Specify the type of
diabetes

diabetes

1
2
3

If you have other
medical condition, not
listed, please specify
If diabetic, how likely
do you think
uncontrolled high blood
sugar could harm your
developing baby by
causing birth defects or
other serious health
problems?
How likely do you think
uncontrolled asthma
could harm your
developing baby by
causing birth defects or
other serious health
problems?

othcon

Gestational
Type I
Type II
Text

diabet1

Likert Scale

1-5

asthma

Likert Scale

1-5
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Question
Have you ever had
gestational diabetes?

Variable name
gestdia

Categories
Yes, in a previous
pregnancy only
Yes, in the current
pregnancy only
Yes, in a previous
pregnancy and in the
current pregnancy
No, never had
gestational diabetes
No, never been
pregnant before

Value
1
2
3

4
5

Did you plan to get
planchld
pregnant with this child?

Yes
No, not now
No, not at any time

Were you or your
bcontr
partner doing anything
to try to prevent
becoming pregnant with
this child?

Yes
No

If Yes, which method
were you using?

Condoms
Diaphragm
Birth control pills
Withdrawal
IUD
Rhythm
Depo Provera,
Implanon or Norplant
Other

If other method used,
please specify
Did you take any fertility
drugs to help you get
pregnant with this child,
like Clomid, Metrodin,
Fertinex, or Pergonal?
If fertility drug taken,
please specify
Have you or members
of your immediate
family (mother or

bcontr1

othmtd

Text

fertdrg

Yes
No

fertdrg1

Text

bdefh

Yes
No
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1
2
3
1
0

1
2
3
4
5
6
7
8

1
0

1
0

Question
sisters) or the
immediate family of
your baby’s father had
any babies with birth
defects (including
babies that might not
have survived)?
If ‘Yes’, please specify
Down syndrome

Variable name

Categories

bdefhs1

Yes
No

1
0

Cleft lip or palate

bdefhs2

Yes
No

1
0

Neural tube defect

bdefhs3

Yes
No

1
0

Cystic fibrosis

bdefhs4

Yes
No

1
0

Heart defect

bdefhs5

Yes
No

1
0

Other

bdefhs6

1
0

If other, please specify
What is the date your
baby is due to be born?
How was your due date
estimated

bdoth
bdate

Yes
No
text
Date (mm/dd/yy)

1
2
3

What is the gestational
age of your baby?
How many times
(including this
pregnancy) have you
been pregnant?
How many live-born
children have you had?
Have you ever had a
miscarriage (<20 wk of
gestation). If yes, how
many?
Have you ever had a
stillborn child (≥ 20 wk
of gestation). If yes,
how many?
Have you ever had a
pregnancy terminated?

gestage

Last menstrual period
Ultrasound
Physical exam
Continuous

gravid

Continuous

parity

Continuous

miscrg

If no, then ‘0’
If yes, then Continuous

stillbrn

If no, then ‘0’
If yes, then Continuous

termin

If no, then ‘0’
If yes, then Continuous

dateest1, 2, and
3
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Value

Question
If yes, how many?
Have you ever had an
ectopic pregnancy. If
yes, how many?
For this pregnancy, how
many weeks after your
last menstrual period
did you first think you
were pregnant?
For this pregnancy, how
many weeks after your
last menstrual period
did you first go to see
a doctor or other health
care provider or go to
the clinic for prenatal
care?
Have you had any
complications in this
pregnancy so far?
Bleeding

Variable name

Categories

Value

ectop

If no, then ‘0’
If yes, then Continuous

realize

Continuous

prenwk

Continuous

bleed

Yes
No

1
0

High blood pressure

highbp

Yes
No

1
0

Diabetes

diabet

Yes
No

1
0

Other

othcom

Yes
No

1
0

If other, please specify
Have you experienced
morning sickness
during this pregnancy?

othcoms
mornsick

Text
Yes
No

1
0

USE OF MEDICATIONS AND SUPPLEMENTS DURING
PREGNANCY
Did you take a
multivit
multivitamin regularly (4
times a week or more)
during the month before
your last menstrual
period?
Have you taken any
vitreg
VITAMINS regularly (4
times/week or more)
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Yes
No

1
0

Yes, multivitamins
Yes, a single vitamin
No

1
2
3

Question
since you became
pregnant?
If “Yes”, then specify
If Brand name vitamin
taken, then specify
If “yes” when did you
start taking vitamins?
How many days during
the last week did you
take vitamins?
Have you taken any
DIETARY
SUPPLEMENTS
(including iron
supplements) or
HERBAL PRODUCTS
on a regular basis since
your last menstrual
period?

Variable name

Categories

vitRx
vitregname

Prescription
OTC
Text

vitdate
vitwk
vitdays

Date (mm/dd/yy) or 0
Continuous or 0
Continuous

herbsup

Yes
No

1
0

Herbs
Tablets or capsules
Teas
Other
Text
Regularly
When I feel sick
Text

1
2
3
4

If ‘Yes’ to herbal
herbsup1
products, please specify
If other, please specify
How often do you take
them?
If taken regularly,
specify time
Please specify any
other dietary
supplements or
products and reason for
taking it
Product1,Reason/Condi
tion
Produc2,Reason/Condit
ion
Product3,Reason/Condi
tion

herboth
herboft
herbreg

Value
1
2

1
2

Text

suppl1;reas1
suppl2;reas2
suppl3;reas3

Have you had any
crave
cravings for non-food
items or really “strange”
foods?
If ‘yes’ what did you
item 1
crave, do you eat it, and

Yes
No
If no , then 0
If yes , then text
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1
0

Question
how often do you eat it?

Have you ever taken
recreational drugs?
If Yes, specify the
recreational drug that
you took
Marijuana/Hashish

Heroin

Variable name

Categories

Value

howoft1

Text

eat1

Yes
No

item2

If no , then 0
If yes , then text

howoft2
eat2

Text
Yes
No

item3

If no , then 0
If yes , then text

howoft3

Text

eat3

Yes
No

1
0

recdrug

Yes
No

1
0

hashish

Before pregnancy

1

1 month prior to LMP
or during this
pregnancy

2

1
0

1
0

1

heroin
Before pregnancy

2
1 month prior to LMP
or during this
pregnancy
Have you gone through
methadone treatment?

Cocaine/Crack

1

methtrt
Never

2

Completed treatment
before pregnancy

3

Undergoing treatment
during current
pregnancy

cocaine

1
2
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Question

Variable name

Categories
Before pregnancy

Inhalants (Glue,
solvent)

inhalant

1 month prior to LMP
or during this
pregnancy

Value
1
2

Before pregnancy
1 month prior to LMP
or during this
pregnancy

methamp
Methamphetamines

recdrug1

Before pregnancy

when1

1 month prior to LMP
or during this
pregnancy

1
2

Other (name)
1
2
Continuous
recdrug2
Before pregnancy

Other (name)

1

when2
1 month prior to LMP
or during this
pregnancy

2

Continuous
Before pregnancy
1 month prior to LMP
or during this
pregnancy
If respondent used >=1
drug(s) 1 month prior to
LMP or during this
pregnancy
Did you discuss the
safety of medications in
pregnancy with any
health care provider
(physician,
nurse-midwife,
physician assistant, or
pharmacist)?
Have you had any

recdrugpreg

Yes
No

1
0

safdis

Yes
No

1
0

vaccine

Yes

1
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Question
vaccinations since your
last menstrual period
If yes to vaccinations,
then please specify
Flu

Variable name

Categories
No

Value
0

vaccineF

Yes
No

1
0

vaccineO

Yes
No
Text

1
0

Yes
No

1
0

Other
If vaccination other than Othvacc
flu, then specify
Have you taken any
presmed
medications
PRESCRIBED by your
doctor or any other
health care provider
since your last
menstrual period, even
if you stopped taking
them once you knew
you were pregnant?
During this pregnancy,
did you take any
OVER-THE-COUNTER
MEDICATIONS (sold
without prescription)?
If yes, please specify

otcmed

Yes
No

1
0

Pain/fever medications

pain

Yes
No

1
0

Nasal Decongestants,
Allergy, Cough
Medications

allrgy

Yes
No

1
0

antdiar

Yes
No

1
0

digesmed

Yes
No

1
0

Heartburn, Dyspepsia,
Antiemetic, Laxative
Medications

antfungl

Yes
No

1
0

Antifungal Medications
(taken for vaginal yeast
infection or thrash)

nicoreth

Yes
No

1
0

Antidiarrheal
Medications
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Question
Nicotine Replacement
Therapy (for smoking
cessation)

Variable name

Categories

Value

tylenol

Yes
No

1
0

tylenolP

Likert Scale

1-5

aspirin

Yes
No

1
0

aspirinP

Likert Scale

1-5

ibuprof

Yes
No

1
0

ibuprofP

Likert Scale

1-5

ketopro

Yes
No

1
0

ketoproP

Likert Scale

1-5

naprox

Yes
No

1
0

naproxP

Likert Scale

1-5

chlorph

Yes
No

1
0

chlorphP

Likert Scale

1-5

OTC Medications and
their perceptions
Acetaminophen
(Tylenol)

Aspirin

Ibuprofen (Advil,
Motrin)

Ketoprofen (Orudis)

Naproxen (Aleve)

Chlorpheniramine
(Chlor-Trimeton)
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Question

Variable name
benadrl

Categories
Yes
No

Value
1
0

benadrlP

Likert Scale

1-5

sudafed

Yes
No

1
0

sudafedP

Likert Scale

1-5

clarzyr

Yes
No

1
0

clarzyrP

Likert Scale

1-5

pepbsml

Yes
No

1
0

pepbsmlP

Likert Scale

1-5

usechngA

Yes
No

1
0

usechngB
Discontinued the use
upon recognition of
pregnancy

Yes
No

1
0

usechngC

Yes
No

1
0

Decreased the use
(dose or frequency)

usechngD

Yes
No

1
0

usechngE

Yes
No

1
0

Benadryl

Pseudoephedrine
(Sudafed)

Kaopectate, Pepto
Bismol
If you took prescription
medications regularly
before you got
pregnant, did you
change the use of these
medications when
you realized you are
pregnant?
Did not take prescription
medications regularly
before pregnancy

Increased the use
Stayed the same,
continued without any
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Question
change

Variable name

Categories

If discontinued the use
upon recognition of
pregnancy, please
specify medication
name

usechng2

Text

If decreased the use
(dose or frequency),
please specify
medication name

usechng3

Text

If Increased the use,
please specify
medication name
If medication stayed the
same, specify
medication name
If you changed the use
of a medication upon
recognition of
pregnancy, why?

usechng4

Text

usechng5

Text

medchng

If other, then specify

chngoth

Provider
recommendation
Family or friend
suggestion
Self-initiated
Financial constraints
Other
Text
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Value

1
2
3
4
5

Question
If a women plans a
pregnancy or finds out
that she is currently
pregnant, she should

Variable name
pregplan

Categories
Stop taking all
medications
immediately to protect
the baby

Value
1

2
Continue taking only
those medications that
are absolutely
necessary and check
with her doctor to see
if the medications are
safe for the baby
Continue taking
necessary medications 3
but reduce the dose or
the number of days
you take them to limit
the amount that gets to
the baby
Continue with all
4
medications as
needed since
medications are safe
for the baby
When a woman uses
medications regularly
during pregnancy, how
often can medications
cause birth defects?

medbdef

Never
Sometimes
Often
Very Often
Always

1
2
3
4
5

Which statement best
describes your view
about women drinking
alcohol during
pregnancy?

pregalc

Pregnant women
should abstain from
drinking any alcohol
(even small amounts)
during pregnancy

1

It is OK for a woman to 2
have an occasional
drink during pregnancy
as long as it is not
more often than once a
week
3
It is OK for a woman to
have an occasional
drink during pregnancy
as long as it is not
more often than one
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Question

Variable name

Categories
drink per day

Value
4

It is OK for a woman to
have an occasional
drink during pregnancy
as long as it is not
more often than two
5
drinks per day

During your current
pregnancy, have you
ever asked with anyone
about the safety of
medications you are
taking for your baby?
If yes, please specify:
Your primary care
doctor or provider

It is OK for a woman to
drink during pregnancy
as long as she does
not drink hard liquor
(i.e., vodka, whiskey,
brandy) but only drinks
wine or beer
Yes
1
No
0

safemed

safemed1

Yes
No

1
0

Your OB/GYN doctor or
midwife

safemed2

Yes
No

1
0

A pharmacist

safemed3

Yes
No

1
0

A member of your
family, spouse

safemed4

Yes
No

1
0

A friend, partner

safemed5

Yes
No

1
0

Other

safemed6

Yes
No

1
0

Any other Hx provider

safemed7

1
0

If other, please specify
Please check any
sources below in which
you have looked for

safeoth

Yes
No
Text
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Question
information about the
safety of medications
for your baby?

I have never looked at
any of these sources
about the safety of
medications for my
baby.

Variable name

Categories

Value

babyinfA

Yes
No

1
0

babyinfB

Yes
No

1
0

babyinfC

Yes
No

1
0

babyinfD

Yes
No

1
0

babyinfE

Yes
No

1
0

babyinfF

Yes
No

1
0

babyinfG

Yes
No

1
0

babyinfH

Yes
No

1
0

babyinf2

Text

babyinf6

Text

insulin

Yes
No
Yes
No

An internet web site(s).
A book.
A magazine
Pregnancy information
telephone
service/hotline (i.e.,
OTIS, Nurse Advisory
Line)
Other
I have not had any
questions about the
safety of medications
for my baby and have
not looked at any of
these sources.
Clinic pamphlet or
brochure
If checked an internet
website, please specify
the name of the website
If used any other
source, please specify
Is the patient currently
on Insulin
Is the patient currently
on any oral
hypoglycemic ?

oralhypo

157

1
0
1
0

Question
If yes, specify the type

Perception regarding
Insulin use
Perception regarding
Sulfonylurea (Oral
Hypoglycemic) use
Perception regarding
Biguanid (Oral
Hypoglycemic) use
Perception regarding
Thiazolidinedione (Oral
Hypoglycemic) use
Is the patient currently
on ICS
Is the patient currently
on BetaA
Is the patient currently
on steriod
Perception regarding
ICS use
Perception regarding
BetaA use
Perception regarding
steroid use
Is the patient currently
on Antipsychotics
Is the patient currently
on Nortiptyline
Is the patient currently
on Bupropion
Is the patient currently
on Citalopram
Is the patient currently
on Escitalopram
Is the patient currently
on Fluoxetine
Is the patient currently
on Paroxetine
Is the patient currently
on Sertraline
Is the patient currently

Variable name
sulfnylu

Categories
Yes
No

Value
1
0

biguanid

Yes
No

1
0

TZD
insulinP

Yes
No
Likert scale

1
0
1-5

sulfnylP

Likert scale

1-5

bguanidP

Likert scale

1-5

TZDP

Likert scale

1-5

ICS

ICSP

Yes
No
Yes
No
Yes
No
Likert scale

1
0
1
0
1
0
1-5

BetaAP

Likert scale

1-5

SteriodP

Likert scale

1-5

Antipsychotics

Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes

1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1

BetaA
Steriod

Nortiptyline
Bupropion
Citalopram
Escitalopram
Fluoxetine
Paroxetine
Sertraline
Venlafaxine
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Question
on Venlafaxine
Perception regarding
Nortiptyline use
Perception regarding
Antipsychotics use
Perception regarding
Bupropion use
Perception regarding
Citalopram use
Perception regarding
Escitalopram use
Perception regarding
Fluoxetine use
Perception regarding
Paroxetine use
Perception regarding
Sertraline use
Perception regarding
Venlafaxine use
\Any comments?

Variable name
AntipsychoticsP

Categories
No
Likert scale

Value
0
1-5

NortiptylineP

Likert scale

1-5

BupropionP

Likert scale

1-5

CitalopramP

Likert scale

1-5

EscitalopramP

Likert scale

1-5

FluoxetineP

Likert scale

1-5

ParoxetineP

Likert scale

1-5

SertralineP

Likert scale

1-5

VenlafaxineP

Likert scale

1-5

comment

Text

PERINATAL DATA ABSTRACTION
Pregnancy outcome

pregoutc

Live-born infant
Spontaneous abortion
(no live birth;
gestational age less
than 20 weeks)
Stillbirth (no live birth;
gestational age 20
weeks or
greater)Ectopic
pregnancy
Termination
Lost to follow-up

1
2

3

4
5

Was this a multiple
birth?

multbir

Yes, twins
Yes, triplets
No

6
1
2
3

Date of delivery or end
of pregnancy?

pregend

Date (mm/dd/yy)
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Question
Cocaine present in
Medical Record

Question
Gestational age at end of
pregnancy
Type of delivery?

If cesarian section,
reason for surgical
delivery?

Variable name
CocianeMR

Variable
name
gestageE

Categories
Yes
No

Value
1
0

Categories

Value

Continuous

deltype

Vaginal – vertex
Vaginal – breech
Vaginal – transverse
Cesarian sectionprimary
Cesarian section –
repeat

1
2
3
4
5

Emergency
Failure to progress
through labor
Elective (pre-planned)
Not applicable
Breech presentation

1
2

pretox

Yes
No

1
0

HBP

Yes
No

1
0

oligohyd

Yes
No

1
0

infect

Yes
No

1
0

gediabts

Yes
No

1
0

otcomp

Yes
No

1
0

csectn

6

3
4
5

Maternal
complications:
Preeclampsia or toxemia
High blood pressure
Oligohydramnios
Infection or fever at
delivery
Gestational diabetes
Other
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If “Other”, specify
What was mother’s
weight at the end of
pregnancy?
What was mother’s
weight gain during
pregnancy?
Is mother breastfeeding
the infant?

otcomps
endwt

Text
Continuous

wtgain

Continuous

brstfeed

Infant ID
Question

infntID
Variable
name
sex

Yes
No
N/A
Text
Categories

Sex of a child
Birth weight
Birth length
Birth head circumference
Apgar Score 1 minute
Apgar Score 5 minute
Neonatal
complications:

Value

Boy
Girl
Continuous
Continuous
Continuous
Continuous
Continuous

1
2

respdist

Yes
No

1
0

hypglycm

Yes
No

1
0

tachypn

Yes
No

1
0

bradycd

Yes
No

1
0

sepsis

Yes
No

1
0

otcompn

Yes
No

1
0

otcompns
stranom

Text
Yes
No

1
0

hospdays

Continuous

infICU

Yes
No

bweight
blength
bheadcf
Apgar1
Apgar5

Respiratory distress
Hypoglycemia
Tachypnea
Bradycardia
Sepsis
Other
If “Other”, specify
Major structural anomaly
diagnosed during the
hospital stay?
How many days was
infant in the hospital?
Was the infant in
Intensive Care Unit?

1
0
2
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1
0

Did infant go home with
the mother?
If ‘No’, what is the
reason?

infhome

Yes
No
Still in nursery

infhomeN

Neonatal death

If ‘Other’, specify reason
Any
abnormalities/conditions
diagnosed in neonatal
period
If Yes, specify
Notes

1
0
1
2

Orphanage

3

Other

4

othomes
abncon

Text
Yes
No

1
0

abncons
Notes

Text
Text

MAJOR DRUG CATEGORIES
Question
Nutrients and Nutritional
Agents
Hematological Agents
Endocrine and Metabolic
Agents
Cardiovasculars

Variable
name
nutrients
hematolog
endocmetab
cardiovasc

Renal and Genitourinary
Agents
Respiratory Agents

renalgenitour

Central Nervous System
Agents
Gastrointestinal Agents

cns
gastro

Anti-Infectives, Systemic

antiinfect

Biological and
Immunological Agents
Dermatological Agents

bioimmun

respiratory

dermatol

Ophthalmic and Otic
Agents
Antineoplastic Agents

ophthal
antineoplast

Herbalife(Herbal Life)

Herbalife
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Categories

Value

Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No

1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0
1
0

Fish Oil(Omega-3l DHA;
Expecta; DHA Expecta;
Omega fats)
Chamomile
(Manzanilla, German
chamomile, Roman
Chamomile)
Valerian
(Valeriana)
Primrose Oil
(Evening primrose oil;
Primrose pill; primrose oil
capsule)
Cranberry
(Cranberry extract,
cranberry tea)
Raspberry
(Red Raspberry;
Raspberry Leaf)
Flax Seed

Fish_Oil

Yes
No

1
0

Chamomile

Yes
No

1
0

Valerian

Yes
No
Yes
No

1
0
1
0

Cranberry

Yes
No

1
0

Raspberry

Yes
No

1
0

Flax_Seed

Other

Other_Herb

Yes
No
Yes
No
Text

1
0
1
0

Herb drug

If Yes, specify the name
of herb

Primrose_Oil

Herb_specify
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APPENDIX B QUESTIONNAIRE OF THE SMART STUDY
GENERAL INFORMATION
1. Date of interview:

__ /__ /__

(month/day/year)

2. Location of interview:
_________________________________________________________
3. Prenatal care provider’s last name:
_______________________________________________
4. Examiner’s last name:
_________________________________________________________
5. Patient’s phone number: ______________________________________________

DEMOGRAPHIC / LIFESTYLE INFORMATION
6. How old are you? ________________ (years)
7. What is your marital status now?
[

] Single, never married

[

] Married, living with spouse

[

] Not married, but living with partner

[ ] Separated from spouse
[ ] Divorced
[ ] Widowed
8. Are you Hispanic, Latino or of Spanish descent?
9. How do you describe yourself:
[ ] White, non-Hispanic

[ ] Yes

[ ] No

(check all that apply)
or

[ ] White, Hispanic

[

] Black or African American

[
[

] American Indian or Alaskan Native - Please specify [ ] tribe or
] pueblo

[ ] Asian or Asian American or Pacific Islander
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[

] Some other group(s) – please specify: _______________________

[ ] Prefer not to report
10. What is the highest level in school you have completed?
[ ] Less than high school graduate
[ ] High school graduate or GED
[ ] Some college or vocational school
[ ] College degree
[ ] Masters, doctorate or professional degree
11. What is your health insurance status?
[ ] No insurance
[

] Employer-based insurance

[

] Self-purchased insurance

[ ] Medicaid
[ ] Other public insurances
( [ ] Indian Health Service, [ ] VA, [ ] First Choice, [ ] UNM/UNMCARE)
11a. Does your insurance cover prescription drugs?
12. Were you born in the Unites States?

[ ] Yes

[ ] Yes

[ ] No
[ ] No

If ‘Yes’, go to question 13. If ‘No’, please answer questions 12a and 12b.
12a. Did you move to the United States:
[ ] With your parents when you were a child
[ ] When you were an adult (≥18 years old)
12b. How long have you lived in the United States: ____________ years
13. What language do you mostly use at home?
[ ] English
[ ] Spanish
[

] Some other language – specify:_________________________ __________
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14. Do you currently smoke cigarettes or use tobacco?

[ ] Yes

[ ] No

14a. How many cigarettes do you
14b. Have you smoked >100
usually smoke in one day? _______
cigarettes in your life?

[ ] Yes

[ ] No

14c. When did you stop smoking?
* Go to the next question
[

] Before I became pregnant

[

] After I realized that I was pregnant

15. Have you ever drank alcohol in your life (e.g., beer, wine, hard liquor, mixed
drinks)?
[ ] Yes
[ ] No
If ‘yes,’ continue to questions 15a and 15b. If ‘no,’ continue to 21a.
15a. How many drinks does it take before you begin to feel the first effect of alcohol?
________
15b. How many drinks typically can you hold before passing out or falling asleep?
________
a. What was the first day of your last menstrual period ___/___/___
(mm/dd/yy)?
I would like you to think back to that period and tell me about your drinking at
that time.
16. During a month or so around your last menstrual period before you got pregnant,
how many times did you drink 4 or more drinks on one occasion? __________
Now I want you to think of 12 months before you got pregnant (a year prior to your
LMP)
17. During the year before you got pregnant, did close friends or relatives worry or
complain about your drinking habits?
[ ] Yes
[ ] No
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18. During the year before you got pregnant, did you ever take a drink first thing in
the morning to get yourself going?
[ ] Yes
[ ] No
19. During the year before you got pregnant, did a friend or family member tell you
about things you said or did while you were drinking that you could not remember?
[ ] Yes
[ ] No
20. During the year before you got pregnant, did you feel you need to cut down on
your drinking?
[ ] Yes

[ ] No
[TWEAK High: ______; TWEAK Hold: ______]

MEDICAL AND REPRODUCTIVE HEALTH
21a. What was your pre-pregnancy weight? ____________ pounds
21b. What was your pre-pregnancy height? ____________ feet/inches
[Researcher Calculated BMI: _______________ ]
22. Do you have a medical condition or problem that requires ongoing, periodic, or
occasional treatment?
[ ] Yes
[ ] No
22a. If yes, check all that apply:
[
[
[
[
[
[
[
[

] Hypertension (high blood pressure)
[ ] Depression
] Diabetes:
[ ] Gestational
[ ] Type I
[ ] Type II
] Anxiety
[ ] Seizure disorder (i.e., epilepsy)
] Migraine headaches
[ ] Thyroid disorder
] Rheumatoid arthritis
] Asthma or allergies
[ ] Heart disease
] Cancer
[ ] Hepatitis
] Other(s) problem - specify: _______________________________

If ‘Yes’ to diabetes, please answer questions 23 and 24. If ‘No’, skip to
question 26.
If ‘Yes’ to asthma, please answer question 25. If ‘No,’ skip to question 26.
23. Have you ever had gestational diabetes?
[ ] Yes, in a previous pregnancy only
[ ] Yes, in the current pregnancy only
[ ] Yes, in a previous pregnancy and in the current pregnancy
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[ ] No, never had gestational diabetes
[ ] No, never been pregnant before
24. How likely do you think uncontrolled high blood sugar could harm your
developing baby by causing birth defects or other serious health problems?
one number)
1
Not at all

2
Unlikely
likely to harm

3
Somewhat
to cause harm

(circle

4
5
Likely
Very likely
likely to harm to harm to cause
harm

25. How likely do you think asthma exacerbations requiring hospitalization or
unscheduled clinic visits could harm your developing baby?
(circle one number)
1
Not at all

2
Unlikely
likely to harm

3
Somewhat
to cause harm

4
5
Likely
Very likely
likely to harm to harm to cause
harm

26. Did you plan to get pregnant with this child?
[ ] Yes

[ ] No, not now [ ] No, not at any time

27. Were you or your partner doing anything to try to prevent becoming pregnant with
this child?
[ ] Yes

[ ] No

27a. If Yes, which method were you using?
[ ] Condoms

[ ] Diaphragm

[

[ ] Withdrawal

[ ] IUD

[ ] Rhythm

[ ] Depo Provera, Implanon or Norplant
_______________________

]

Birth control pills

[ ] Other:

28. Did you take any fertility drugs to help you get pregnant with this child, like
Clomid, Metrodin, Fertinex, or Pergonal?
[ ] Yes
[ ] No
28a. If Yes, which drugs did you use? ________________________________
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29. Have you or members of your immediate family (mother or sisters) or the
immediate family of your baby’s father had any babies with birth defects (including
babies that might not have survived)?
[ ] Yes

[ ] No

* If ‘No’, go to question 30. If ‘Yes’, please specify:
Down syndrome

[ ] Yes

[ ] No

Cleft lip or palate

[ ] Yes

[ ] No

Neural tube defect

[ ] Yes

[ ] No

Cystic fibrosis

[ ] Yes

[ ] No

Heart defect

[ ] Yes

[ ] No

Other

[ ] Yes

[ ] No

If “Yes,” please specify:______________________________
30. What was the first day of your last menstrual period?__ __ / __ __ /__ __ (mm /
dd / yy)
31. What is the date your baby is due to be born: ___ ___ / ___ ___ / ___ ___ (mm /
dd / yy)
31a. What is the gestational age of your baby? ___________ weeks
31b. How was your due date estimated?
By:
[ ] Last menstrual period
[ ] Ultrasound
[ ] Physical exam
32. How many times (including this pregnancy) have you been pregnant?
_____________
If this is the 1st pregnancy put “1”for q. 32 and “0” for questions 33-37 & skip to
question 37.
33. How many live-born children have you had? ___________
If no live-born children or this is the first pregnancy, then put “0”
34. Have you ever had a miscarriage (<20 wk of gestation). If yes, how
many?_______
If never had a miscarriage, put “0”
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35. Have you ever had a stillborn child (≥ 20 wk of gestation). If yes, how
many?______
If never had a stillborn child, put “0”
36. Have you ever had a pregnancy terminated? If yes, how many?_______
If never had a termination, put “0”
37. Have you ever had an ectopic pregnancy. If yes, how many?_________
If never had an ectopic pregnancy, put “0”
38. For this pregnancy, how many weeks after your last menstrual period did you first
think you were pregnant? _________
39. For this pregnancy, how many weeks after your last menstrual period did you first
go to see a doctor or other health care provider or go to the clinic for prenatal care?
__________
40a. Have you had any complications in this pregnancy so far?
(* Please check yes or no for each complication)
- Bleeding
- High blood pressure
- Diabetes
- Other

[
[
[
[

] Yes
] Yes
] Yes
] Yes

[
[
[
[

] No
] No
] No
] No

40b. If “other”, please specify: ____________________________________
41. Have you experienced morning sickness during this pregnancy?
[ ] Yes[ ] No
USE OF MEDICATIONS AND SUPPLEMENTS DURING PREGNANCY
42. Did you take a multivitamin regularly (4 times a week or more) during the month
before your last menstrual period?
[ ] Yes

[ ] No

43. Have you taken any VITAMINS regularly (4 times/week or more) since you
became pregnant?
43a. [ ] Yes, multivitamins [ ] Yes, a single vitamin
[ ] No
If ‘Yes,’ answer questions 43b-43e.
43b. [ ] Prescription
43c. [

[ ] OTC

] Brand name: _______________________________

43d. When did you start taking vitamins?
______________ (mm/dd/yy) ____________ (gestational weeks)
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43e. How many days during the last week did you take vitamins? ________
(days/week)
44a. Have you taken any DIETARY SUPPLEMENTS (including iron supplements)
or
HERBAL PRODUCTS on a regular basis since your last menstrual period?
[ ] Yes

[ ] No

44b. If ‘Yes’ to herbal products, please specify:

[ ] Herbs

[ ] Tablets or capsules
[ ] Teas
[ ] Other: _____________________________
[

44c. How often do you take them?
] When I feel sick

[

] Regularly: _____ times per ______ or

Please specify any other dietary supplements or products and reason for taking
it:
Product 1:_______________ Reason/Condition: _______________________
Product 2: _______________Reason/Condition: _______________________
Product 3: _______________Reason/Condition: _______________________
44d. Have you had any cravings for non-food items or really “strange” foods?
[ ] Yes
[ ] No
If ‘yes’ what did you crave, do you eat it, and how often do you eat it?
Item 1: _________ Eat it? [ ] Yes [ ] No;

How often? ____________

Item 2: _________Eat it? [

] No;

How often? ____________

Item 3: __________Eat it? [ ] Yes [ ] No;

How often? ___________

] Yes

[

45. Have you ever taken any recreational drugs?
[ ] Yes

[ ] No

If ‘Yes’ please specify the recreational drug name(s) and when it was used:
Check if taken:
[ ] Marijuana/Hashish: [ ] Before pregnancy
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[ ] 1 month prior to LMP or during this pregnancy
[ ] Heroin:

[ ] Before pregnancy
[ ] 1 month prior to LMP or during this pregnancy

Have you gone through methadone treatment?
[ ] Never
[ ] Completed treatment before pregnancy
[ ] Undergoing treatment during current pregnancy
[ ] Cocaine/Crack:
[

[ ] Before pregnancy
[ ] 1 month prior to LMP or during this pregnancy

] Inhalants (glue, solvent):

[ ] Before pregnancy
[ ] 1 month prior to LMP or during this pregnancy

[ ] Methamphetamines:

[ ] Before pregnancy
[ ] 1 month prior to LMP or during this pregnancy

[ ] Other: ____________

[ ] Before pregnancy
[ ] 1 month prior to LMP or during this pregnancy

[ ] Other: ____________

[ ] Before pregnancy
[ ] 1 month prior to LMP or during this pregnancy

46. Did you discuss the safety of medications in pregnancy with any health care
provider (physician, nurse-midwife, physician assistant, or pharmacist)?
[ ] Yes

[ ] No

47a. Have you had any vaccinations since your last menstrual period?
[ ] Yes
47b. If Yes to vaccinations, please specify: [

[ ] No

] Flu

[ ] Other: _________________
48. Have you taken any medications PRESCRIBED by your doctor or any other
health care provider since your last menstrual period, even if you stopped taking them
once you knew you were pregnant?
[ ] Yes
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[ ] No

If ‘Yes’ please specify the medication name, reason for taking it, and your perception
of how likely it is that this medication might be harmful for your baby if taken during
pregnancy:
a. Medication 1:_________________________

Indication: __________________

How likely do you think it is that this medication could harm your developing
baby by causing birth defects or other serious health problems: (circle one
number)
1
Not at all

2
Unlikely
likely to harm

3
Somewhat
to cause harm

4
5
Likely
Very likely
likely to harm to harm to cause
harm

b. Medication 2:___________________________ Indication: __________________
How likely is it that this medication could harm your developing baby by
causing birth defects or other serious health problems:
(circle one number)
1
Not at all

2
Unlikely
likely to harm

3
Somewhat
to cause harm

4
5
Likely
Very likely
likely to harm to harm to cause
harm

c. Medication 3:___________________________ Indication: __________________
How likely is it that this medication could harm your developing baby by
causing birth defects or other serious health problems:
(circle one number)
1
Not at all

2
Unlikely
likely to harm

3
Somewhat
to cause harm

4
5
Likely
Very likely
likely to harm to harm to cause
harm

d. Medication 4:___________________________ Indication: __________________
How likely is it that this medication could harm your developing baby by
causing birth defects or other serious health problems:
(circle one number)
1
Not at all

2
Unlikely
likely to harm

3
Somewhat
to cause harm
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4
5
Likely
Very likely
likely to harm to harm to cause
harm

e. Medication 5:________________________

Indication: __________________

How likely is it that this medication could harm your developing baby by
causing birth defects or other serious health problems:
(circle one number)
1
Not at all

2
Unlikely
likely to harm

3
Somewhat
to cause harm

4
5
Likely
Very likely
likely to harm to harm to cause
harm

49. During this pregnancy, did you take any OVER-THE-COUNTER
MEDICATIONS (sold without prescription)?
[ ] Yes
[ ] No
Check all medications that you have actually taken since your last menstrual period,
even if you stopped taking them once you knew you were pregnant. Then for
medications you took since pregnancy, please specify your perception of how likely
each medication is to cause birth defects or other problems for your baby.
Pain/Fever Medications:
Rate all medications:
1
2
Not at all
Unlikely
likely to harm

3
Somewhat
to cause harm

4
5
Likely
Very likely
likely to harm to harm to cause
harm

[ ] Acetaminophen (Tylenol)

1

2

3

4

5

[ ] Aspirin

1

2

3

4

5

[ ] Ibuprofen (Advil, Motrin)

1

2

3

4

5

[ ] Ketoprofen (Orudis)

1

2

3

4

5

[ ] Naproxen (Aleve)

1

2

3

4

5

[

] Other medication –
1
2
3
4
5
specify: ________________________________________________________

Nasal Decongestants, Allergy, Cough Medications:
Rate all medications:
1
2
3
4
5
Not at all
Unlikely
Somewhat
Likely
Very likely
likely to harm
to cause harm likely to harm to harm to cause
harm
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[ ] Chlorpheniramine (Chlor-Trimeton) 1

2

3

4

5

[ ] Benadryl

1

2

3

4

5

[

1

2

3

4

5

1

2

3

4

5

] Pseudoephedrine (Sudafed)

[ ] Claritin, Zyrtec
[

] Other medication –
1
2
3
4
5
specify:________________________________________________________

Antidiarrheal Medications:
Rate all medications:
1
2
Not at all
Unlikely
likely to harm

3
Somewhat
to cause harm

4
5
Likely
Very likely
likely to harm to harm to cause
harm

Check if taken:
[

] Kaopectate, Pepto Bismol

1

2

3

4

5

[

] Loperamide (Imodium)

1

2

3

4

5

[

] Other medication –
1
2
3
4
5
specify: _______________________________________________________

Heartburn, Dyspepsia, Antiemetic, Laxative Medications:
Rate all medications:
1
2
Not at all
Unlikely
likely to harm

3
Somewhat
to cause harm

4
5
Likely
Very likely
likely to harm to harm to cause
harm

Check if taken:
[ ] Maalox, Mylanta Gas

1

2

3

4

5

[ ] Tums

1

2

3

4

5

[ ] Tagamet, Zantac, Axid, Pepcid

1

2

3

4

5

[ ] Colace

1

2

3

4

5

[ ] Correctol, Dulcolax, Ex-Lax

1

2

3

4

5

[ ] Senna, fiber products

1

2

3

4

5

[ ] Unisom

1

2

3

4

5
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[

] Other medication –
1
2
3
4
5
specify:_______________________________________________________

Antifungal Medications (taken for vaginal yeast infection or thrash):
Rate all medications:
1
Not at all

2
Unlikely
likely to harm

3
Somewhat
to cause harm

4
5
Likely
Very likely
likely to harm to harm to cause
harm

Check if taken:
[ ] Vaginal cream or suppositories 1
(Monistat, Vagistat, Femstat, Lotrim)
[

2

3

4

5

] Other medication –
1
2
3
4
5
specify:_______________________________________________________

Nicotine Replacement Therapy (for smoking cessation):
Rate all medications:
1
2
Not at all
Unlikely
likely to harm

3
Somewhat
to cause harm

4
5
Likely
Very likely
likely to harm to harm to cause
harm

Check if taken:
[

]

Nicotine gum, spray or inhaler 1

2

3

4

5

[ ] Nicotine patch

1

2

3

4

5

[

1

2

3

4

5

]

Other medication –

specify:________________________________________________________

Other over-the-counter medications you have taken while pregnant:
Rate all medications:
1
2
Not at all
Unlikely
likely to harm

3
Somewhat
to cause harm
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4
5
Likely
Very likely
likely to harm to harm to cause
harm

Check if taken:
[ ] Other medication –
1
specify: ___________________

2

3

4

5

[ ] Other medication –
1
specify: __________________

2

3

4

5

[ ] Other medication –
1
specify: __________________

2

3

4

5

50. If you took prescription medications regularly before you got pregnant, did you
change the use of these medications when you realized you are pregnant?
[ ] Did not take prescription medications regularly before pregnancy
[ ] Discontinued the use upon recognition of pregnancy.
Medication___________
[ ] Decreased the use (dose or frequency). Medication: _______________
[

] Increased the use. Medication: ______________________________

[

] Stayed the same, continued without any change. Medication: __________

50a. If you changed the use of a medication upon recognition of pregnancy, why?
[

] Provider recommendation

[

] Family or friend suggestion

[ ] Self-initiated
[ ] Financial constraints
[ ] Other:
_____________________________________________________________
Now I’m going to ask you about your thoughts about medication use during
pregnancy in general. Please check the answer you think is the most appropriate for
each question.
51. If a woman plans a pregnancy or finds out that she is currently pregnant, she
should:
[

] Stop taking all medications immediately to protect the baby

[

] Continue taking only those medications that are absolutely necessary and
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check with her doctor to see if the medications are safe for the baby
[

] Continue taking necessary medications but reduce the dose or the number
of days you take them to limit the amount that gets to the baby

[

] Continue with all medications as needed since medications are safe for
the baby

52. When a woman uses medications regularly during pregnancy, how often can
medications cause birth defects?
[ ]
Never

[ ]
Sometimes

[ ]
Often

[ ]
Very Often

[ ]
Always

53. Which statement best describes your view about women drinking alcohol during
pregnancy?
[ ] Pregnant women should abstain from drinking any alcohol (even small
amounts) during pregnancy.
[

] It is OK for a woman to have an occasional drink during pregnancy
as long as it is not more often than once a week.

[

] It is OK for a woman to have an occasional drink during pregnancy
as long as it is not more often than one drink per day.

[

] It is OK for a woman to have an occasional drink during pregnancy
as long as it is not more often than two drinks per day.

[ ] It is OK for a woman to drink during pregnancy as long as she does not
drink hard liquor (i.e., vodka, whiskey, brandy) but only drinks wine or
beer.
54. During your current pregnancy, have you ever asked anyone about the safety of
medications you are taking for your baby?
[ ] Yes
[ ] No
54a. If yes, check any individuals who you have asked a question about the safety
of any medications for your baby: (Check all that apply to you)
[

] Your primary care doctor or provider

[ ] Your OB/GYN doctor or midwife
[ ] A pharmacist
[ ] A member of your family, spouse
[ ] A friend, partner
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[ ] Other - specify:
_________________________________________________________
[ ] Any other heath care provider
55. Please check any sources below in which you have looked for information about
the safety of medications for your baby? (Check all that apply to you)
[ ] I have never looked at any of these sources about the safety of
medications for my baby
[ ] An internet web site(s).
Specify:_________________________________________________
[ ] A book.
[ ] A magazine
[ ] Pregnancy information telephone service/hotline (i.e., OTIS, Nurse
Advisory Line)
[ ] Other - specify:
______________________________________________________________
[

] I have not had any questions about the safety of medications for my baby
and have not looked at any of these sources.

[

] Clinic pamphlet or brochure

56. NOTES/COMMENTS:
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
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